<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-journal-id">0375410</journal-id><journal-id journal-id-type="pubmed-jr-id">5127</journal-id><journal-id journal-id-type="nlm-ta">J Pediatr</journal-id><journal-id journal-id-type="iso-abbrev">J. Pediatr.</journal-id><journal-title-group><journal-title>The Journal of pediatrics</journal-title></journal-title-group><issn pub-type="ppub">0022-3476</issn><issn pub-type="epub">1097-6833</issn></journal-meta><article-meta><article-id pub-id-type="pmid">29269199</article-id><article-id pub-id-type="pmc">5830079</article-id><article-id pub-id-type="doi">10.1016/j.jpeds.2017.11.012</article-id><article-id pub-id-type="manuscript">EMS75734</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>A Mixed Lipid Emulsion for Prevention of Parenteral Nutrition Associated Cholestasis in Extremely Low Birth Weight Infants: A Randomized Clinical Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Repa</surname><given-names>Andreas</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Binder</surname><given-names>Christoph</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Thanhaeuser</surname><given-names>Margarita</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kreissl</surname><given-names>Alexandra</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pablik</surname><given-names>Eleonore</given-names></name><degrees>Boecc</degrees><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Huber-Dangl</surname><given-names>Mercedes</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Berger</surname><given-names>Angelika</given-names></name><degrees>MD, MBA</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Haiden</surname><given-names>Nadja</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib></contrib-group><aff id="A1">
<label>1</label>Department of Pediatrics and Adolescent Medicine, Division of Neonatology, Pediatric Intensive Care and Neuropediatrics, Medical University of Vienna, Vienna</aff><aff id="A2">
<label>2</label>Section for Medical Statistics, CeMSIIS, Medical University of Vienna, Vienna, Austria</aff><author-notes><corresp id="CR1">Reprint requests: Andreas Repa, MD, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Waehringer Guertel 18-20, Vienna 1090, Austria. <email>andreas.repa@meduniwien.ac.at</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>16</day><month>1</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>18</day><month>12</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>3</month><year>2018</year></pub-date><volume>194</volume><fpage>87</fpage><lpage>93.e1</lpage><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p></license></permissions><abstract><sec id="S1"><title><offsets xml_i="3975" xml_f="3985" txt_i="11" txt_f="21">Objectives</offsets></title><p id="P1"><offsets xml_i="4004" xml_f="4179" txt_i="22" txt_f="194">To examine whether a mixed lipid emulsion reduces the incidence of parenteral nutrition associated cholestasis (PNAC) in extremely low birth weight (ELBW, &lt;1000 g) infants.</offsets></p></sec><sec id="S2"><title><offsets xml_i="4209" xml_f="4221" txt_i="196" txt_f="208">Study design</offsets></title><p id="P2"><offsets xml_i="4240" xml_f="4784" txt_i="209" txt_f="750">This double-blind randomized trial of 230 ELBW infants (June 2012-October 2015) was performed at a single level IV neonatal intensive care unit. Patients received either a mixed lipid emulsion composed of soybean oil, medium chain triglycerides, olive oil, and fish oil-(intervention) or a soybean oil-based lipid emulsion (control) for parenteral nutrition. The primary outcome measure was PNAC (conjugated bilirubin &gt;1.5 mg/dL [25 μmol/L] at 2 consecutive measurements). The study was powered to detect a reduction of PNAC from 25% to 10%.</offsets></p></sec><sec id="S3"><title><offsets xml_i="4814" xml_f="4821" txt_i="752" txt_f="759">Results</offsets></title><p id="P3"><offsets xml_i="4840" xml_f="5288" txt_i="760" txt_f="1208">Reasons for noneligibility of 274 infants screened were refusal to participate (n = 16), death (n = 10), withdrawal of treatment (n = 5), higher order multiples (n = 9), and parents not available for consent (n = 4). Intention to treat analysis was carried out in 223 infants (7 infants excluded after randomization). Parenteral nutrition associated cholestasis was 11 of 110 (10.1%) in the intervention and 18 of 113 (15.9%) in the control group (</offsets><italic><offsets xml_i="5296" xml_f="5297" txt_i="1208" txt_f="1209">P</offsets></italic><offsets xml_i="5306" xml_f="5443" txt_i="1209" txt_f="1346"> = .20). Multivariable analyses showed no statistically significant difference in the intention to treat (aOR 0.428, 95% CI 0.155-1.187; </offsets><italic><offsets xml_i="5451" xml_f="5452" txt_i="1346" txt_f="1347">P</offsets></italic><offsets xml_i="5461" xml_f="5528" txt_i="1347" txt_f="1414"> = .10) or per protocol population (aOR 0.457, 95% CI 0.155-1.347; </offsets><italic><offsets xml_i="5536" xml_f="5537" txt_i="1414" txt_f="1415">P</offsets></italic><offsets xml_i="5546" xml_f="5633" txt_i="1415" txt_f="1502"> = .16). There was no statistically significant effect on any other neonatal morbidity.</offsets></p></sec><sec id="S4"><title><offsets xml_i="5663" xml_f="5674" txt_i="1504" txt_f="1515">Conclusions</offsets></title><p id="P4"><offsets xml_i="5693" xml_f="5829" txt_i="1516" txt_f="1652">The incidence of parenteral nutrition associated cholestasis was not significantly reduced using a mixed lipid emulsion in ELBW infants.</offsets></p></sec><sec id="S5"><title><offsets xml_i="5859" xml_f="5877" txt_i="1654" txt_f="1672">Trial Registration</offsets></title><p id="P5"><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/"><offsets xml_i="5967" xml_f="5985" txt_i="1673" txt_f="1691">ClinicalTrials.gov</offsets></ext-link><offsets xml_i="5996" xml_f="6009" txt_i="1691" txt_f="1704"> NCT01585935.</offsets></p></sec></abstract></article-meta></front><body><p id="P6"><offsets xml_i="6070" xml_f="6191" txt_i="1713" txt_f="1831">Extremely low birth weight (ELBW, birth weight &lt;1000 g) infants depend on parenteral nutrition (PN) for several weeks.</offsets><xref rid="R1" ref-type="bibr"><offsets xml_i="6222" xml_f="6223" txt_i="1831" txt_f="1832">1</offsets></xref><offsets xml_i="6230" xml_f="6328" txt_i="1832" txt_f="1930"> With ongoing PN, parenteral nutrition associated cholestasis (PNAC) is a well-described pathology</offsets><xref rid="R2" ref-type="bibr"><offsets xml_i="6359" xml_f="6360" txt_i="1930" txt_f="1931">2</offsets></xref><offsets xml_i="6367" xml_f="6403" txt_i="1931" txt_f="1967"> that may progress to liver failure.</offsets><xref rid="R3" ref-type="bibr"><offsets xml_i="6434" xml_f="6435" txt_i="1967" txt_f="1968">3</offsets></xref><offsets xml_i="6442" xml_f="6505" txt_i="1968" txt_f="2031"> Soybean oil-based lipid emulsions are rich in proinflammatory </offsets><italic><offsets xml_i="6513" xml_f="6514" txt_i="2031" txt_f="2032">ω</offsets></italic><offsets xml_i="6523" xml_f="6592" txt_i="2032" txt_f="2101">-6 long chain polyunsaturated fatty acids (LC-PUFAs) and phytosterols</offsets><xref rid="R4" ref-type="bibr"><offsets xml_i="6623" xml_f="6624" txt_i="2101" txt_f="2102">4</offsets></xref><offsets xml_i="6631" xml_f="6670" txt_i="2102" txt_f="2141"> that are both accused to trigger PNAC.</offsets><xref rid="R5" ref-type="bibr"><offsets xml_i="6701" xml_f="6702" txt_i="2141" txt_f="2142">5</offsets></xref><offsets xml_i="6709" xml_f="6710" txt_i="2142" txt_f="2143">,</offsets><xref rid="R6" ref-type="bibr"><offsets xml_i="6741" xml_f="6742" txt_i="2143" txt_f="2144">6</offsets></xref><offsets xml_i="6749" xml_f="6901" txt_i="2144" txt_f="2296"> To overcome these untoward effects alternative oil-based lipid emulsions were developed. Here, the latest generation contains fish oil, which provides </offsets><italic><offsets xml_i="6909" xml_f="6910" txt_i="2296" txt_f="2297">ω</offsets></italic><offsets xml_i="6919" xml_f="6975" txt_i="2297" txt_f="2353">-3 LC-PUFAs—that are less proinflammatory compared with </offsets><italic><offsets xml_i="6983" xml_f="6984" txt_i="2353" txt_f="2354">ω</offsets></italic><offsets xml_i="6993" xml_f="7035" txt_i="2354" txt_f="2396">-6 LC-PUFAs—and is devoid of phytosterols.</offsets><xref rid="R4" ref-type="bibr"><offsets xml_i="7066" xml_f="7067" txt_i="2396" txt_f="2397">4</offsets></xref><offsets xml_i="7074" xml_f="7237" txt_i="2397" txt_f="2560"> Infants with PNAC because of intestinal failure who were treated with a lipid emulsion exclusively based on fish oil showed marked improvements of liver function.</offsets><xref rid="R7" ref-type="bibr"><offsets xml_i="7268" xml_f="7269" txt_i="2560" txt_f="2561">7</offsets></xref><offsets xml_i="7276" xml_f="7277" txt_i="2561" txt_f="2562">,</offsets><xref rid="R8" ref-type="bibr"><offsets xml_i="7308" xml_f="7309" txt_i="2562" txt_f="2563">8</offsets></xref><offsets xml_i="7316" xml_f="7684" txt_i="2563" txt_f="2931"> Most recently, a mixed lipid emulsion composed of soybean oil, medium chain triglycerides (MCTs), olive oil, and fish oil (SMOF-LE) has become available, and is licensed for pediatric use in the European Union, but not the US because of insufficient data to date on adequate supply with essential fatty acids (EFA). Because of its mixed nature, SMOF-LE contains less </offsets><italic><offsets xml_i="7692" xml_f="7693" txt_i="2931" txt_f="2932">ω</offsets></italic><offsets xml_i="7702" xml_f="7712" txt_i="2932" txt_f="2942">-6 LC-PUFA</offsets><xref rid="R4" ref-type="bibr"><offsets xml_i="7743" xml_f="7744" txt_i="2942" txt_f="2943">4</offsets></xref><offsets xml_i="7751" xml_f="7752" txt_i="2943" txt_f="2944">,</offsets><xref rid="R9" ref-type="bibr"><offsets xml_i="7783" xml_f="7784" txt_i="2944" txt_f="2945">9</offsets></xref><offsets xml_i="7791" xml_f="7808" txt_i="2945" txt_f="2962"> and phytosterols</offsets><xref rid="R10" ref-type="bibr"><offsets xml_i="7840" xml_f="7842" txt_i="2962" txt_f="2964">10</offsets></xref><offsets xml_i="7849" xml_f="7859" txt_i="2964" txt_f="2974"> but more </offsets><italic><offsets xml_i="7867" xml_f="7868" txt_i="2974" txt_f="2975">ω</offsets></italic><offsets xml_i="7877" xml_f="7918" txt_i="2975" txt_f="3016">-3 LC-PUFA and also more alpha-tocopherol</offsets><xref rid="R4" ref-type="bibr"><offsets xml_i="7949" xml_f="7950" txt_i="3016" txt_f="3017">4</offsets></xref><offsets xml_i="7957" xml_f="7958" txt_i="3017" txt_f="3018">,</offsets><xref rid="R9" ref-type="bibr"><offsets xml_i="7989" xml_f="7990" txt_i="3018" txt_f="3019">9</offsets></xref><offsets xml_i="7997" xml_f="8403" txt_i="3019" txt_f="3425"> compared with soybean oil-based lipid emulsion. Parenteral nutrition using SMOF-LE may, therefore, prevent PNAC compared with the current standard soybean oil-based lipid emulsion. We therefore hypothesized that PN using SMOF-LE would reduce PNAC in ELBW infants. The current trial was set up to compare SMOF-LE and soybean oil-based lipid emulsion for PN of ELBW infants with PNAC as the primary outcome.</offsets></p><sec sec-type="methods" id="S6"><title><offsets xml_i="8446" xml_f="8453" txt_i="3426" txt_f="3433">Methods</offsets></title><p id="P7"><offsets xml_i="8472" xml_f="8525" txt_i="3434" txt_f="3487">This double-blind randomized controlled trial (RCT) (</offsets><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/"><offsets xml_i="8596" xml_f="8614" txt_i="3487" txt_f="3505">ClinicalTrials.gov</offsets></ext-link><offsets xml_i="8625" xml_f="8669" txt_i="3505" txt_f="3549">: NCT01585935) was performed at the level IV</offsets><xref rid="R11" ref-type="bibr"><offsets xml_i="8701" xml_f="8703" txt_i="3549" txt_f="3551">11</offsets></xref><offsets xml_i="8710" xml_f="9574" txt_i="3551" txt_f="4412"> neonatal care unit of the University Children’s Hospital Vienna (Medical University of Vienna, Vienna, Austria). The primary aim was to assess whether a mixed lipid emulsion (SMOF-LE) would reduce PNAC in ELBW infants compared with a soybean oil-based lipid emulsion. Secondary aims were to explore the impact on other morbidities. Recruitment was initiated in June 2012. Eligible participants were ELBW infants admitted before 24 hours of life. Infants with cholestasis (conjugated bilirubin &gt;1.5 mg/dL [25 μmol/L]) before intervention and higher order multiples were not eligible. Infants with conditions associated with cholestasis independent of PN (ie, infection with cytomegalovirus, HIV, hepatitis B or C, rhesus mediated hemolysis, cystic fibrosis, inborn errors of metabolism or primary liver diseases) were not eligible or excluded postrandomization.</offsets><xref rid="R12" ref-type="bibr"><offsets xml_i="9606" xml_f="9608" txt_i="4412" txt_f="4414">12</offsets></xref><offsets xml_i="9615" xml_f="9781" txt_i="4414" txt_f="4577"> Participants were randomized using permuted blocks (ratio 1:1, block size of 4) and stratified according to sex and birth weight (&lt;750 vs ≥750 g) using a software</offsets><xref rid="R13" ref-type="bibr"><offsets xml_i="9813" xml_f="9815" txt_i="4577" txt_f="4579">13</offsets></xref><offsets xml_i="9822" xml_f="10055" txt_i="4579" txt_f="4812"> prepared by an independent statistician, who kept the randomization sequence concealed until the end of the study. To account for correlation of twins, the first twin was randomized and the second assigned to the opposite treatment.</offsets><xref rid="R14" ref-type="bibr"><offsets xml_i="10087" xml_f="10089" txt_i="4812" txt_f="4814">14</offsets></xref><offsets xml_i="10096" xml_f="10338" txt_i="4814" txt_f="5056"> Intervention was started within the first 120 hours of life. Infants received either a mixed lipid emulsion composed of 30% soybean oil, 30% MCT, 25% olive oil, and 15% fish oil (SMOFlipid 20%; Fresenius Kabi, Bad Homburg, Germany; SMOF-LE; </offsets><italic><offsets xml_i="10346" xml_f="10347" txt_i="5056" txt_f="5057">ω</offsets></italic><offsets xml_i="10356" xml_f="10359" txt_i="5057" txt_f="5060">-6:</offsets><italic><offsets xml_i="10367" xml_f="10368" txt_i="5060" txt_f="5061">ω</offsets></italic><offsets xml_i="10377" xml_f="10520" txt_i="5061" txt_f="5204">-3 ratio 2.5:1) or a soybean oil-based lipid emulsion (Intralipid 20%; Fresenius Kabi, Bad Homburg, Germany; soybean oil-based lipid emulsion; </offsets><italic><offsets xml_i="10528" xml_f="10529" txt_i="5204" txt_f="5205">ω</offsets></italic><offsets xml_i="10538" xml_f="10541" txt_i="5205" txt_f="5208">-6:</offsets><italic><offsets xml_i="10549" xml_f="10550" txt_i="5208" txt_f="5209">ω</offsets></italic><offsets xml_i="10559" xml_f="10869" txt_i="5209" txt_f="5519">-3 ratio 8:1) for PN over 24 hours. Both products have similar side effects and are registered for infants in Europe, but in the US SMOFlipid 20% (Fresenius Kabi, Bad Homburg, Germany) is only registered for adults. Based on a content of 35 mg/mL (range: 28-50) linoleic acid and a requirement of 0.25 g/kg/day</offsets><xref rid="R15" ref-type="bibr"><offsets xml_i="10901" xml_f="10903" txt_i="5519" txt_f="5521">15</offsets></xref><offsets xml_i="10910" xml_f="11019" txt_i="5521" txt_f="5630"> to prevent EFA deficiency, SMOF-LE theoretically will prevent EFA deficiency at 1.4 g/kg/day (range: 1-1.8).</offsets></p><p id="P8"><offsets xml_i="11034" xml_f="11083" txt_i="5631" txt_f="5680">Based on a prevalence of PNAC of 25% at our unit,</offsets><xref rid="R16" ref-type="bibr"><offsets xml_i="11115" xml_f="11117" txt_i="5680" txt_f="5682">16</offsets></xref><offsets xml_i="11124" xml_f="11127" txt_i="5682" txt_f="5685"> a </offsets><italic><offsets xml_i="11135" xml_f="11136" txt_i="5685" txt_f="5686">χ</offsets></italic><sup><offsets xml_i="11150" xml_f="11151" txt_i="5686" txt_f="5687">2</offsets></sup><offsets xml_i="11157" xml_f="11415" txt_i="5687" txt_f="5945"> test indicated that 100 infants/group were required to detect a relative reduction by 60% (from 25% to 10%) with a 2-sided 5% significance level and a power of 80%. Assuming a dropout rate of 18%, we aimed at recruiting 122 infants/group in a 3-year period.</offsets></p><p id="P9"><offsets xml_i="11430" xml_f="13327" txt_i="5946" txt_f="7834">Participants, healthcare providers, data collectors, and outcome adjudicators were blinded. The investigational products were visually indistinguishable. Taste or smell was regarded irrelevant because of the closed mode of application; study lipids were stored at room temperature and applied using light protected syringes and infusion lines. A blinding team uninvolved in clinical decisions established the blinding code and masked the glass containers using opaque labels designated “Lipid A” or “Lipid B.” Labels were resistant to detachment, in particular by 70% alcohol used during aseptic preparation. Neonatal nurses who prepared the study lipids for PN were part of the blinding team. Discarded containers were controlled for blinding integrity. The attending physicians prescribed the study lipids together with PN using a computer program (catoPAN; Cato Software Solutions, Becton Dickinson, Vienna, Austria) customized to include the designations “Lipid A” and “Lipid B.” Participants received full PN from birth using soybean oil-based lipid emulsion (1 g/kg/day) and were switched to study lipids after enrollment. Lipids were dosed up to 3 g/kg/day at the discretion of the attending physicians and reduced in relation to enteral nutrition (increased up to 20 mL/kg/day). Serum triglycerides were measured at least weekly. Lipids were halted for 24 hours at triglyceride levels &gt;400 mg/dL (4.5 mmol/L) or down titrated &gt;250 mg/dL (2.8 mmol/L). Parenteral nutrition was stopped at 140-160 mL/kg/day of enteral feeds. Urodeoxycholic acid was administered to patients that developed cholestasis. Parenteral fish oil (Omegaven; Fresenius Kabi, Bad Homburg, Germany) was permitted as rescue therapy (1 g/kg/day) if conjugated bilirubin was &gt;6 mg/dL (100 μmol/L). Infants were followed until their 44th week of postmenstrual age (PMA), discharge, or transfer to another hospital.</offsets></p><p id="P10"><offsets xml_i="13343" xml_f="13609" txt_i="7835" txt_f="8101">Patient data were collected from the electronic charts (ICCA; Phillips Medical Systems, Eindhoven, The Netherlands) and discharge letters. Data on PN were collected from the prescription software (catoPAN; Cato Software Solutions, Becton Dickinson, Vienna, Austria).</offsets></p><p id="P11"><offsets xml_i="13625" xml_f="13679" txt_i="8102" txt_f="8156">Demographic characteristics were recorded as shown in </offsets><xref ref-type="table" rid="T1"><offsets xml_i="13711" xml_f="13718" txt_i="8156" txt_f="8163">Table I</offsets></xref><offsets xml_i="13725" xml_f="13726" txt_i="8163" txt_f="8164">.</offsets></p><p id="P12"><offsets xml_i="13742" xml_f="13957" txt_i="8165" txt_f="8377">A full course of prenatal steroids was defined as 2 doses of betamethasone administered 24 hours apart. Surfactant (Curosurf; Chiesi, Parma, Italy) was administered to all infants &lt;28 + 0 weeks of gestational age</offsets><xref rid="R17" ref-type="bibr"><offsets xml_i="13989" xml_f="13991" txt_i="8377" txt_f="8379">17</offsets></xref><offsets xml_i="13998" xml_f="14199" txt_i="8379" txt_f="8577"> or else if deficiency was suspected (&gt;35% oxygen with saturation ranges of 88%-96%). Anthropometry was performed by the attending nurses and z scores calculated using growth curves by Fenton et al.</offsets><xref rid="R18" ref-type="bibr"><offsets xml_i="14231" xml_f="14233" txt_i="8577" txt_f="8579">18</offsets></xref><offsets xml_i="14240" xml_f="14241" txt_i="8579" txt_f="8580">,</offsets><xref rid="R19" ref-type="bibr"><offsets xml_i="14273" xml_f="14275" txt_i="8580" txt_f="8582">19</offsets></xref><offsets xml_i="14282" xml_f="14377" txt_i="8582" txt_f="8671"> Small for gestational age was defined as birth weight &lt;10th percentile (z score &lt;–1.28).</offsets></p><p id="P13"><offsets xml_i="14393" xml_f="14498" txt_i="8672" txt_f="8777">The primary outcome PNAC, measures of liver function, and neonatal morbidities were recorded as shown in </offsets><xref ref-type="table" rid="T2"><offsets xml_i="14530" xml_f="14538" txt_i="8777" txt_f="8785">Table II</offsets></xref><offsets xml_i="14545" xml_f="14546" txt_i="8785" txt_f="8786">.</offsets></p><p id="P14"><offsets xml_i="14562" xml_f="14665" txt_i="8787" txt_f="8887">PNAC was defined as conjugated bilirubin levels &gt;1.5 mg/dL (25 μmol/L) at 2 consecutive measurements</offsets><xref rid="R16" ref-type="bibr"><offsets xml_i="14697" xml_f="14699" txt_i="8887" txt_f="8889">16</offsets></xref><offsets xml_i="14706" xml_f="14902" txt_i="8889" txt_f="9085"> by spectrophotometric quantitation (Vitros Chemistry System; Ortho Clinical Diagnostics, Raritan, New Jersey). Peak levels of liver enzymes (aspartate aminotransferase, alanine aminotransferase, </offsets><italic><offsets xml_i="14910" xml_f="14911" txt_i="9085" txt_f="9086">γ</offsets></italic><offsets xml_i="14920" xml_f="15667" txt_i="9086" txt_f="9833">-glutamyltransferase [GT], and alkaline phosphatase [AP]) during hospitalization were identified. Blood sampling was performed weekly as long as PN was required and then every 7-14 days. Retinopathy of prematurity (ROP) was screened for by indirect ophthalmoscopy starting at 5 weeks of age. Treatment (laser or intravitreal ranibizumab) was performed at ROP stage ≥3. Culture proven sepsis was detected by blood culture (BacT/Alert Pediatric FAN; BioMerieux, Marcy l’Etoile, France) drawn after birth and before any antibiotic treatment. Intraventricular hemorrhage and cystic periventricular leukomalacia were diagnosed by cerebral ultrasound performed every 7-14 days. Necrotizing enterocolitis (NEC) was diagnosed clinically (Bell’s stage ≥IIa</offsets><xref rid="R20" ref-type="bibr"><offsets xml_i="15699" xml_f="15701" txt_i="9833" txt_f="9835">20</offsets></xref><offsets xml_i="15708" xml_f="15859" txt_i="9835" txt_f="9986">) or after surgical exploration. Focal intestinal perforation was defined as perforation in an otherwise healthy bowel. All infants received probiotics</offsets><xref rid="R21" ref-type="bibr"><offsets xml_i="15891" xml_f="15893" txt_i="9986" txt_f="9988">21</offsets></xref><offsets xml_i="15900" xml_f="15917" txt_i="9988" txt_f="10005"> and lactoferrin.</offsets><xref rid="R22" ref-type="bibr"><offsets xml_i="15949" xml_f="15951" txt_i="10005" txt_f="10007">22</offsets></xref><offsets xml_i="15958" xml_f="16230" txt_i="10007" txt_f="10276"> Bronchopulmonary dysplasia (BPD) was defined as supplementary oxygen after 36 + 0 weeks PMA. Persistent ductus arteriosus was treated if hemodynamically significant (enddiastolic blood flow in the left pulmonary artery &gt;20 cm/s or backward flow in the abdominal aorta)</offsets><xref rid="R23" ref-type="bibr"><offsets xml_i="16262" xml_f="16264" txt_i="10276" txt_f="10278">23</offsets></xref><offsets xml_i="16271" xml_f="16433" txt_i="10278" txt_f="10440"> using ibuprofen. Pulmonary hypertension was diagnosed by measurement of tricuspid regurgitation or right-to-left/bidirectional shunt across the ductus arteriosus</offsets><xref rid="R24" ref-type="bibr"><offsets xml_i="16465" xml_f="16467" txt_i="10440" txt_f="10442">24</offsets></xref><offsets xml_i="16474" xml_f="16534" txt_i="10442" txt_f="10502"> and treated using inhaled nitric oxide, sildenafil or both.</offsets></p><p id="P15"><offsets xml_i="16550" xml_f="16619" txt_i="10503" txt_f="10572">Data on study lipids, nutrition and growth were recorded as shown in </offsets><xref ref-type="table" rid="T3"><offsets xml_i="16651" xml_f="16660" txt_i="10572" txt_f="10581">Table III</offsets></xref><offsets xml_i="16667" xml_f="16668" txt_i="10581" txt_f="10582">.</offsets></p><p id="P16"><offsets xml_i="16684" xml_f="16812" txt_i="10583" txt_f="10708">Therapy adherence was calculated as the percentage study lipids were correctly provided; &gt;80% was considered highly adherent.</offsets><xref rid="R25" ref-type="bibr"><offsets xml_i="16844" xml_f="16846" txt_i="10708" txt_f="10710">25</offsets></xref><offsets xml_i="16853" xml_f="17151" txt_i="10710" txt_f="11008"> Enteral feeds were provided every 3 hours; the median volume of a single feed per kg in the first week of life was calculated. For growth analysis (anthropometry with z score difference from birth to discharge), only survivors were analyzed to avoid distortion of measurements by perimortal edema.</offsets></p><sec id="S7"><title><offsets xml_i="17175" xml_f="17195" txt_i="11009" txt_f="11029">Statistical Analyses</offsets></title><p id="P17"><offsets xml_i="17215" xml_f="17219" txt_i="11030" txt_f="11034">The </offsets><italic><offsets xml_i="17227" xml_f="17228" txt_i="11034" txt_f="11035">χ</offsets></italic><sup><offsets xml_i="17242" xml_f="17243" txt_i="11035" txt_f="11036">2</offsets></sup><offsets xml_i="17249" xml_f="17404" txt_i="11036" txt_f="11191"> test was used to examine the relationship between the intervention and PNAC. The primary outcome was additionally analyzed by binary logistic regression (</offsets><xref ref-type="table" rid="T4"><offsets xml_i="17436" xml_f="17444" txt_i="11191" txt_f="11199">Table IV</offsets></xref><offsets xml_i="17451" xml_f="17524" txt_i="11199" txt_f="11272">). Possible confounders were specified according to literature (male sex,</offsets><xref rid="R26" ref-type="bibr"><offsets xml_i="17556" xml_f="17558" txt_i="11272" txt_f="11274">26</offsets></xref><offsets xml_i="17565" xml_f="17573" txt_i="11274" txt_f="11282"> sepsis,</offsets><xref rid="R27" ref-type="bibr"><offsets xml_i="17605" xml_f="17607" txt_i="11282" txt_f="11284">27</offsets></xref><offsets xml_i="17614" xml_f="17698" txt_i="11284" txt_f="11368"> compound outcome of NEC, focal intestinal perforation and gastrointestinal surgery,</offsets><xref rid="R28" ref-type="bibr"><offsets xml_i="17730" xml_f="17732" txt_i="11368" txt_f="11370">28</offsets></xref><offsets xml_i="17739" xml_f="17753" txt_i="11370" txt_f="11384"> birth weight,</offsets><xref rid="R29" ref-type="bibr"><offsets xml_i="17785" xml_f="17787" txt_i="11384" txt_f="11386">29</offsets></xref><offsets xml_i="17794" xml_f="17812" txt_i="11386" txt_f="11404"> total days on PN,</offsets><xref rid="R3" ref-type="bibr"><offsets xml_i="17843" xml_f="17844" txt_i="11404" txt_f="11405">3</offsets></xref><offsets xml_i="17851" xml_f="17876" txt_i="11405" txt_f="11430"> z score of birth weight,</offsets><xref rid="R16" ref-type="bibr"><offsets xml_i="17908" xml_f="17910" txt_i="11430" txt_f="11432">16</offsets></xref><offsets xml_i="17917" xml_f="17985" txt_i="11432" txt_f="11500"> and enteral nutrition in the first week of life per kg birth weight</offsets><xref rid="R16" ref-type="bibr"><offsets xml_i="18017" xml_f="18019" txt_i="11500" txt_f="11502">16</offsets></xref><offsets xml_i="18026" xml_f="18229" txt_i="11502" txt_f="11705">) and tested in univariable logistic regression models for significant influence. Because of the low number of events the confounders included in the final model were restricted to those with univariate </offsets><italic><offsets xml_i="18237" xml_f="18238" txt_i="11705" txt_f="11706">P</offsets></italic><offsets xml_i="18247" xml_f="18457" txt_i="11706" txt_f="11913"> &lt; .01. Furthermore, the covariates of the final model were reduced according to Akaike information criterion to avoid overfitting. Secondary outcome measures were compared between the treatment groups with </offsets><italic><offsets xml_i="18465" xml_f="18466" txt_i="11913" txt_f="11914">χ</offsets></italic><sup><offsets xml_i="18480" xml_f="18481" txt_i="11914" txt_f="11915">2</offsets></sup><offsets xml_i="18487" xml_f="18531" txt_i="11915" txt_f="11959"> test for categorical data and Mann-Whitney </offsets><italic><offsets xml_i="18539" xml_f="18540" txt_i="11959" txt_f="11960">U</offsets></italic><offsets xml_i="18549" xml_f="18747" txt_i="11960" txt_f="12158"> test for continuous data. Analyses were performed by intention to treat (ITT). As sensitivity analysis, calculations were additionally carried out on the per protocol set (treatment adherence ≥80%,</offsets><xref rid="R25" ref-type="bibr"><offsets xml_i="18779" xml_f="18781" txt_i="12158" txt_f="12160">25</offsets></xref><offsets xml_i="18788" xml_f="18952" txt_i="12160" txt_f="12324"> admission ≥28 days according to the study protocol). Because of opposed allocation of twins, calculations including the mother as random factor were not necessary.</offsets><xref rid="R14" ref-type="bibr"><offsets xml_i="18984" xml_f="18986" txt_i="12324" txt_f="12326">14</offsets></xref><offsets xml_i="18993" xml_f="19024" txt_i="12326" txt_f="12357"> There was no interim analysis.</offsets></p><p id="P18"><offsets xml_i="19040" xml_f="19350" txt_i="12358" txt_f="12668">The study was conducted in conformance with the Declaration of Helsinki, International Conference on Harmonisation / Good Clinical Practice guidelines, and the respective European Union directives embedded in the Austrian drug act. Written consent from 1 parent was sufficient due to low risk for participants.</offsets><xref rid="R30" ref-type="bibr"><offsets xml_i="19382" xml_f="19384" txt_i="12668" txt_f="12670">30</offsets></xref><offsets xml_i="19391" xml_f="19590" txt_i="12670" txt_f="12869"> Patients were insured as legally required. The study was approved by the institution’s ethic committee (EK 2011/1030) and registered at European Clinical Trial Database (EudraCT 2011-005456-33) and </offsets><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/"><offsets xml_i="19661" xml_f="19679" txt_i="12869" txt_f="12887">clinicaltrials.gov</offsets></ext-link><offsets xml_i="19690" xml_f="19705" txt_i="12887" txt_f="12902"> (NCT01585935).</offsets></p></sec></sec><sec sec-type="results" id="S8"><title><offsets xml_i="19760" xml_f="19767" txt_i="12905" txt_f="12912">Results</offsets></title><p id="P19"><offsets xml_i="19787" xml_f="19906" txt_i="12913" txt_f="13032">A total of 274 ELBW infants were screened: 223 infants were available for ITT analysis, 206 for per protocol analysis (</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="19936" xml_f="19942" txt_i="13032" txt_f="13038">Figure</offsets></xref><offsets xml_i="19949" xml_f="19964" txt_i="13038" txt_f="13053">; available at </offsets><ext-link ext-link-type="uri" xlink:href="http://www.jpeds.com"><offsets xml_i="20028" xml_f="20041" txt_i="13053" txt_f="13066">www.jpeds.com</offsets></ext-link><offsets xml_i="20052" xml_f="20511" txt_i="13066" txt_f="13525">). Three participants did not receive the intervention (death: n = 2; error: n = 1), 3 participants were withdrawn due to conditions associated with cholestasis (mitochondriopathy: n = 1; Gaucher disease type II: n = 1; undefined genetic syndrome: n = 1), and 1 participant was withdrawn due to cholestasis before intervention. Thus, 7 participants (SMOF-LE: n = 4; soybean oil-based lipid emulsion: n = 3) were excluded from ITT analysis after randomization.</offsets><xref rid="R12" ref-type="bibr"><offsets xml_i="20543" xml_f="20545" txt_i="13525" txt_f="13527">12</offsets></xref><offsets xml_i="20552" xml_f="20832" txt_i="13527" txt_f="13807"> Recruitment ended after the intended number of participants was included (July 2015); follow-up lasted until October 2015. Premature unblinding (accidentally or as a result of a serious adverse event) did not occur. All analyses were prespecified according to the study protocol.</offsets></p><p id="P20"><offsets xml_i="20848" xml_f="20889" txt_i="13808" txt_f="13849">Demographic characteristics are shown in </offsets><xref ref-type="table" rid="T1"><offsets xml_i="20921" xml_f="20928" txt_i="13849" txt_f="13856">Table I</offsets></xref><offsets xml_i="20935" xml_f="21073" txt_i="13856" txt_f="13994">. Study participants were born between 23 + 1 and 33 + 4 weeks PMA (median 26 + 0 weeks) and weighed between 390 and 998 g (median 775 g).</offsets></p><p id="P21"><offsets xml_i="21089" xml_f="21251" txt_i="13995" txt_f="14157">The primary outcome PNAC was 36% lower using SMOFLE compared with soybean oil-based lipid emulsion, a relative difference that was statistically not significant (</offsets><xref ref-type="table" rid="T2"><offsets xml_i="21283" xml_f="21291" txt_i="14157" txt_f="14165">Table II</offsets></xref><offsets xml_i="21298" xml_f="21719" txt_i="14165" txt_f="14586">). We found no significant difference in PNAC characteristics, highest conjugated bilirubin, or liver enzymes. Mortality, hospitalization, culture proven sepsis and morbidity (visual, gastrointestinal, neurologic, cardiovascular, and pulmonary) did not differ significantly. Infants receiving fish oil as a rescue therapy did not differ between groups in mortality (SMOF-LE: 0/3 vs soybean oil-based lipid emulsion: 1/4; </offsets><italic><offsets xml_i="21727" xml_f="21728" txt_i="14586" txt_f="14587">P</offsets></italic><offsets xml_i="21737" xml_f="21841" txt_i="14587" txt_f="14691"> = .35) or normalization of PNAC until discharge (SMOFLE: 1/3 vs soybean oil-based lipid emulsion: 0/4; </offsets><italic><offsets xml_i="21849" xml_f="21850" txt_i="14691" txt_f="14692">P</offsets></italic><offsets xml_i="21859" xml_f="21979" txt_i="14692" txt_f="14812"> = .21). A multivariable model including relevant confounders showed no significant difference for the primary outcome (</offsets><xref ref-type="table" rid="T4"><offsets xml_i="22011" xml_f="22019" txt_i="14812" txt_f="14820">Table IV</offsets></xref><offsets xml_i="22026" xml_f="22028" txt_i="14820" txt_f="14822">).</offsets></p><p id="P22"><offsets xml_i="22044" xml_f="22097" txt_i="14823" txt_f="14876">Therapy adherence was high and equal between groups (</offsets><xref ref-type="table" rid="T3"><offsets xml_i="22129" xml_f="22138" txt_i="14876" txt_f="14885">Table III</offsets></xref><offsets xml_i="22145" xml_f="22553" txt_i="14885" txt_f="15293">). Both groups received PN for a comparable time with similar amounts of lipids. Triglyceride levels were measured at similar intravenous lipid supply and did not differ significantly, as well as the incidence of hypertriglyceridemia. Feeding volumes in the first week of life and the use of mother’s milk were similar. There was no significant difference in anthropometry from birth to the end of the study.</offsets></p></sec><sec sec-type="discussion" id="S9"><title><offsets xml_i="22605" xml_f="22615" txt_i="15295" txt_f="15305">Discussion</offsets></title><p id="P23"><offsets xml_i="22635" xml_f="22940" txt_i="15306" txt_f="15611">In this prospective, double-blind randomized trial in ELBW infants a mixed lipid emulsion composed of soybean oil, MCT, olive oil, and fish oil did not significantly reduce the incidence of PNAC compared with a soybean oil-based lipid emulsion. We found no effect on measures such as ROP, BPD, and growth.</offsets></p><p id="P24"><offsets xml_i="22956" xml_f="23085" txt_i="15612" txt_f="15741">Lipid emulsions based on soybean oil are the currently recommended product for provision of parenteral lipids in preterm infants,</offsets><xref rid="R4" ref-type="bibr"><offsets xml_i="23116" xml_f="23117" txt_i="15741" txt_f="15742">4</offsets></xref><offsets xml_i="23124" xml_f="23125" txt_i="15742" txt_f="15743">,</offsets><xref rid="R31" ref-type="bibr"><offsets xml_i="23157" xml_f="23159" txt_i="15743" txt_f="15745">31</offsets></xref><offsets xml_i="23166" xml_f="23226" txt_i="15745" txt_f="15805"> and the only licensed lipid emulsion for infants in the US.</offsets><xref rid="R9" ref-type="bibr"><offsets xml_i="23257" xml_f="23258" txt_i="15805" txt_f="15806">9</offsets></xref><offsets xml_i="23265" xml_f="23411" txt_i="15806" txt_f="15952"> Because side effects of PN on liver function were ascribed to the specific properties of soybean oil, research focused on reducing the excess of </offsets><italic><offsets xml_i="23419" xml_f="23420" txt_i="15952" txt_f="15953">ω</offsets></italic><offsets xml_i="23429" xml_f="23559" txt_i="15953" txt_f="16083">-6 LC-PUFAs and phytosterols in lipid emulsions by admixing alternative oils (MCT and olive) and most recently fish oil providing </offsets><italic><offsets xml_i="23567" xml_f="23568" txt_i="16083" txt_f="16084">ω</offsets></italic><offsets xml_i="23577" xml_f="23623" txt_i="16084" txt_f="16130">-3 LC-PUFAs to counterbalance proinflammatory </offsets><italic><offsets xml_i="23631" xml_f="23632" txt_i="16130" txt_f="16131">ω</offsets></italic><offsets xml_i="23641" xml_f="23652" txt_i="16131" txt_f="16142">-6 effects.</offsets><xref rid="R4" ref-type="bibr"><offsets xml_i="23683" xml_f="23684" txt_i="16142" txt_f="16143">4</offsets></xref><offsets xml_i="23691" xml_f="23799" txt_i="16143" txt_f="16251"> In this regard, SMOFLE is the most recent development and was shown to improve the supply with the crucial </offsets><italic><offsets xml_i="23807" xml_f="23808" txt_i="16251" txt_f="16252">ω</offsets></italic><offsets xml_i="23817" xml_f="23938" txt_i="16252" txt_f="16373">-3 LC-PUFA docosahexaenoic acid (DHA) while lowering soybean oil exposure by 70% and phytosterol exposure by roughly 50%.</offsets><xref rid="R10" ref-type="bibr"><offsets xml_i="23970" xml_f="23972" txt_i="16373" txt_f="16375">10</offsets></xref><offsets xml_i="23979" xml_f="24120" txt_i="16375" txt_f="16516"> Also, the higher supply with vitamin E compared with soybean oil-based lipid emulsion may prevent PNAC as recently shown in preterm piglets.</offsets><xref rid="R32" ref-type="bibr"><offsets xml_i="24152" xml_f="24154" txt_i="16516" txt_f="16518">32</offsets></xref><offsets xml_i="24161" xml_f="24375" txt_i="16518" txt_f="16732"> However, until now clinical trials have not provided enough evidence for improvement of clinical outcomes such as PNAC to justify a change of the current guidelines that recommend soybean oil-based lipid emulsion.</offsets></p><p id="P25"><offsets xml_i="24391" xml_f="24534" txt_i="16733" txt_f="16876">Four out of 6 trials that have tested SMOF-LE vs soybean oil-based lipid emulsion in 310 preterm infants reported on PNAC as secondary outcome,</offsets><xref rid="R33" ref-type="bibr"><offsets xml_i="24566" xml_f="24568" txt_i="16876" txt_f="16878">33</offsets></xref><offsets xml_i="24575" xml_f="24576" txt_i="16878" txt_f="16879">–</offsets><xref rid="R36" ref-type="bibr"><offsets xml_i="24608" xml_f="24610" txt_i="16879" txt_f="16881">36</offsets></xref><offsets xml_i="24617" xml_f="24673" txt_i="16881" txt_f="16937"> without a significant effect in a recent meta-analysis.</offsets><xref rid="R31" ref-type="bibr"><offsets xml_i="24705" xml_f="24707" txt_i="16937" txt_f="16939">31</offsets></xref><offsets xml_i="24714" xml_f="25145" txt_i="16939" txt_f="17370"> However, the overall incidence of PNAC was 5% across studies, therefore, the relatively low number of infants analyzed may not suffice to exclude a clinically meaningful effect. Our trial was the first designed to investigate SMOF-LE for prevention of PNAC as primary outcome. To attain a high baseline incidence, we exclusively recruited the vulnerable group of ELBW infants with an anticipated PNAC incidence of 25% at our unit.</offsets><xref rid="R16" ref-type="bibr"><offsets xml_i="25177" xml_f="25179" txt_i="17370" txt_f="17372">16</offsets></xref><offsets xml_i="25186" xml_f="25399" txt_i="17372" txt_f="17585"> However, the power to prove our hypothesis was lowered by an observed PNAC incidence of only 15.9% in the current trial, attributable to an accelerated weaning from PN compared with the planning phase (−10 days).</offsets><xref rid="R16" ref-type="bibr"><offsets xml_i="25431" xml_f="25433" txt_i="17585" txt_f="17587">16</offsets></xref><offsets xml_i="25440" xml_f="25612" txt_i="17587" txt_f="17759"> This shorter time on PN is an important limitation of our study and possibly related to the implementation of probiotics at our unit before the start of this trial in 2010</offsets><xref rid="R21" ref-type="bibr"><offsets xml_i="25644" xml_f="25646" txt_i="17759" txt_f="17761">21</offsets></xref><offsets xml_i="25653" xml_f="25785" txt_i="17761" txt_f="17893"> and their preventive effect against NEC. Reduced fear of NEC possibly encouraged clinicians to establish full enteral feeds faster.</offsets></p><p id="P26"><offsets xml_i="25801" xml_f="26298" txt_i="17894" txt_f="18391">Although our study showed that SMOF-LE did not significantly prevent PNAC in ELBW, our results cannot be generalized to infants with a substantially longer time on PN such as those with intestinal failure. The same applies to infants with established PNAC. Here, a significant decline of conjugated bilirubin was demonstrated in a pilot RCT after switching from soybean oil-based lipid emulsion to SMOF-LE, however, only after adjusting the original analysis and eliminating a statistical outlier.</offsets><xref rid="R37" ref-type="bibr"><offsets xml_i="26330" xml_f="26332" txt_i="18391" txt_f="18393">37</offsets></xref><offsets xml_i="26339" xml_f="26444" txt_i="18393" txt_f="18498"> In our study, PNAC also resolved more quickly, however, the numbers were not statistically significant (</offsets><xref ref-type="table" rid="T2"><offsets xml_i="26476" xml_f="26484" txt_i="18498" txt_f="18506">Table II</offsets></xref><offsets xml_i="26491" xml_f="26493" txt_i="18506" txt_f="18508">).</offsets></p><p id="P27"><offsets xml_i="26509" xml_f="26604" txt_i="18509" txt_f="18604">Besides protection of liver function, other morbidities associated with prematurity such as BPD</offsets><xref rid="R38" ref-type="bibr"><offsets xml_i="26636" xml_f="26638" txt_i="18604" txt_f="18606">38</offsets></xref><offsets xml_i="26645" xml_f="26770" txt_i="18606" txt_f="18731"> might have been affected by the intervention with SMOF-LE. So far meta-analyses did not show a significant influence on BPD.</offsets><xref rid="R39" ref-type="bibr"><offsets xml_i="26802" xml_f="26804" txt_i="18731" txt_f="18733">39</offsets></xref><offsets xml_i="26811" xml_f="26982" txt_i="18733" txt_f="18904"> On the contrary, Collins et al recently reported their trial of fish oil supplementation in preterm infants and surprisingly found a significantly increased risk for BPD.</offsets><xref rid="R40" ref-type="bibr"><offsets xml_i="27014" xml_f="27016" txt_i="18904" txt_f="18906">40</offsets></xref><offsets xml_i="27023" xml_f="27165" txt_i="18906" txt_f="19048"> In that study, fish oil was used as enteral add-on from birth to 36 weeks PMA providing a total DHA supply even beyond fetal accretion rates.</offsets><xref rid="R40" ref-type="bibr"><offsets xml_i="27197" xml_f="27199" txt_i="19048" txt_f="19050">40</offsets></xref><offsets xml_i="27206" xml_f="27507" txt_i="19050" txt_f="19351"> This is in contrast to our study using SMOF-LE, where fish oil is provided parenterally and only as long as PN was needed. However, Collins et al also questioned the safety of PN using SMOF-LE. We and other RCTs found no difference in BPD using SMOF-LE compared with soybean oil-based lipid emulsion.</offsets><xref rid="R33" ref-type="bibr"><offsets xml_i="27539" xml_f="27541" txt_i="19351" txt_f="19353">33</offsets></xref><offsets xml_i="27548" xml_f="27549" txt_i="19353" txt_f="19354">–</offsets><xref rid="R36" ref-type="bibr"><offsets xml_i="27581" xml_f="27583" txt_i="19354" txt_f="19356">36</offsets></xref><offsets xml_i="27590" xml_f="27708" txt_i="19356" txt_f="19474"> Furthermore, we found no affection of other outcomes related to inflammatory processes such as pulmonary hypertension</offsets><xref rid="R41" ref-type="bibr"><offsets xml_i="27740" xml_f="27742" txt_i="19474" txt_f="19476">41</offsets></xref><offsets xml_i="27749" xml_f="27782" txt_i="19476" txt_f="19509"> and persistent ductus arteriosus</offsets><xref rid="R42" ref-type="bibr"><offsets xml_i="27814" xml_f="27816" txt_i="19509" txt_f="19511">42</offsets></xref><offsets xml_i="27823" xml_f="27869" txt_i="19511" txt_f="19557"> or of any other neonatal morbidity and death.</offsets></p><p id="P28"><offsets xml_i="27885" xml_f="27906" txt_i="19558" txt_f="19579">In recent years, the </offsets><italic><offsets xml_i="27914" xml_f="27915" txt_i="19579" txt_f="19580">ω</offsets></italic><offsets xml_i="27924" xml_f="28009" txt_i="19580" txt_f="19665">-3 LC-PUFA DHA was included into models of ROP as another nonoxygen-regulated factor.</offsets><xref rid="R43" ref-type="bibr"><offsets xml_i="28041" xml_f="28043" txt_i="19665" txt_f="19667">43</offsets></xref><offsets xml_i="28050" xml_f="28150" txt_i="19667" txt_f="19767"> Supplementation with fish oil to improve DHA enrichment of the retina was suggested to prevent ROP.</offsets><xref rid="R43" ref-type="bibr"><offsets xml_i="28182" xml_f="28184" txt_i="19767" txt_f="19769">43</offsets></xref><offsets xml_i="28191" xml_f="28269" txt_i="19769" txt_f="19847"> Here, SMOF-LE would not only provide DHA but also higher amounts of vitamin E</offsets><xref rid="R4" ref-type="bibr"><offsets xml_i="28300" xml_f="28301" txt_i="19847" txt_f="19848">4</offsets></xref><offsets xml_i="28308" xml_f="28330" txt_i="19848" txt_f="19870"> known to prevent ROP.</offsets><xref rid="R44" ref-type="bibr"><offsets xml_i="28362" xml_f="28364" txt_i="19870" txt_f="19872">44</offsets></xref><offsets xml_i="28371" xml_f="28410" txt_i="19872" txt_f="19911"> Two RCTs studied the effect of SMOF-LE</offsets><xref rid="R33" ref-type="bibr"><offsets xml_i="28442" xml_f="28444" txt_i="19911" txt_f="19913">33</offsets></xref><offsets xml_i="28451" xml_f="28473" txt_i="19913" txt_f="19935"> or a pure fish oil LE</offsets><xref rid="R45" ref-type="bibr"><offsets xml_i="28505" xml_f="28507" txt_i="19935" txt_f="19937">45</offsets></xref><offsets xml_i="28514" xml_f="28609" txt_i="19937" txt_f="20032"> on ROP as primary outcome. In the study by Beken et al, SMOF-LE significantly reduced any ROP.</offsets><xref rid="R33" ref-type="bibr"><offsets xml_i="28641" xml_f="28643" txt_i="20032" txt_f="20034">33</offsets></xref><offsets xml_i="28650" xml_f="28785" txt_i="20034" txt_f="20169"> Pawlik et al showed that co-application of a pure fish oil LE and soybean oil-based lipid emulsion significantly prevented severe ROP.</offsets><xref rid="R45" ref-type="bibr"><offsets xml_i="28817" xml_f="28819" txt_i="20169" txt_f="20171">45</offsets></xref><offsets xml_i="28826" xml_f="28924" txt_i="20171" txt_f="20269"> A recent systematic review suggested a preventive effect based on RCTs and observational studies.</offsets><xref rid="R46" ref-type="bibr"><offsets xml_i="28956" xml_f="28958" txt_i="20269" txt_f="20271">46</offsets></xref><offsets xml_i="28965" xml_f="29273" txt_i="20271" txt_f="20579"> In the present study, we did not find any effect against any stage of ROP. Compared with the study by Pawlik et al, we provided less fish oil using SMOF-LE, which may indicate some dose dependency. However, the lack of effect compared with Beken et al (ROP reduced by 80%) who also used SMOF-LE is striking.</offsets><xref rid="R33" ref-type="bibr"><offsets xml_i="29305" xml_f="29307" txt_i="20579" txt_f="20581">33</offsets></xref><offsets xml_i="29314" xml_f="29889" txt_i="20581" txt_f="21156"> In this context, it seems important that infants in our study were more immature by 4 weeks compared with Beken et al. As ROP typically occurs after 30 weeks PMA, the timing of fish oil supplementation from birth and retinal DHA enrichment in relation to the actual PMA probably matters. In this respect, well-designed pharmacologic studies on dosing and timing of SMOF-LE or pure fish oil LE in relation to the actual PMA are necessary. However, it is discouraging that the trial by Collins et al, who applied enteral fish oil in high amounts, also showed no effect on ROP.</offsets><xref rid="R40" ref-type="bibr"><offsets xml_i="29921" xml_f="29923" txt_i="21156" txt_f="21158">40</offsets></xref></p><p id="P29"><offsets xml_i="29946" xml_f="30100" txt_i="21159" txt_f="21313">Safety and tolerance of SMOF-LE is another important issue inconsistently referred to in literature. Although lipid clearance was even improved in adults,</offsets><xref rid="R47" ref-type="bibr"><offsets xml_i="30132" xml_f="30134" txt_i="21313" txt_f="21315">47</offsets></xref><offsets xml_i="30141" xml_f="30342" txt_i="21315" txt_f="21513"> serum triglycerides were found significantly higher in preterm infants using SMOF-LE compared with soybean oil-based lipid emulsion, though at doses exceeding current recommendations (&gt;3 g/kg/day).</offsets><xref rid="R34" ref-type="bibr"><offsets xml_i="30374" xml_f="30376" txt_i="21513" txt_f="21515">34</offsets></xref><offsets xml_i="30383" xml_f="30534" txt_i="21515" txt_f="21666"> In our study, serum triglyceride levels and the incidence of hypertriglyceridemia did not differ between SMOF-LE and soybean oil-based lipid emulsion.</offsets></p><p id="P30"><offsets xml_i="30550" xml_f="30627" txt_i="21667" txt_f="21744">Postnatal growth failure is a frequently observed problem in preterm infants.</offsets><xref rid="R48" ref-type="bibr"><offsets xml_i="30659" xml_f="30661" txt_i="21744" txt_f="21746">48</offsets></xref><offsets xml_i="30668" xml_f="30779" txt_i="21746" txt_f="21857"> Although SMOF-LE and soybean oil-based lipid emulsion provide similar amounts of energy, improved supply with </offsets><italic><offsets xml_i="30787" xml_f="30788" txt_i="21857" txt_f="21858">ω</offsets></italic><offsets xml_i="30797" xml_f="30901" txt_i="21858" txt_f="21962">-3 LC-PUFAs might impact on head growth as DHA rapidly accumulates in the fetal brain in late pregnancy.</offsets><xref rid="R49" ref-type="bibr"><offsets xml_i="30933" xml_f="30935" txt_i="21962" txt_f="21964">49</offsets></xref><offsets xml_i="30942" xml_f="31055" txt_i="21964" txt_f="22077"> Furthermore, a recent meta-analysis of biochemical aspects showed lower levels of arachidonic acid using SMOF-LE</offsets><xref rid="R50" ref-type="bibr"><offsets xml_i="31087" xml_f="31089" txt_i="22077" txt_f="22079">50</offsets></xref><offsets xml_i="31096" xml_f="31193" txt_i="22079" txt_f="22176"> and raised concerns because of an association of low arachidonic acid levels and growth failure.</offsets><xref rid="R51" ref-type="bibr"><offsets xml_i="31225" xml_f="31227" txt_i="22176" txt_f="22178">51</offsets></xref><offsets xml_i="31234" xml_f="31600" txt_i="22178" txt_f="22544"> In our study, we found no significant impact of SMOF-LE on anthropometry. Moreover, there is a lack of studies demonstrating the efficacy of SMOF-LE in the prevention of EFA deficiency in preterm infants. As we did not measure EFA in our study, we can only speculate. A supply of less than 0.25 g/kg/day of linoleic acid may cause EFA deficiency in preterm infants.</offsets><xref rid="R15" ref-type="bibr"><offsets xml_i="31632" xml_f="31634" txt_i="22544" txt_f="22546">15</offsets></xref><offsets xml_i="31641" xml_f="31881" txt_i="22546" txt_f="22786"> It therefore seems prudent to aim at a supply of 2 g/kg/day SMOF-LE if enteral nutrition is low in the first week of life, or likely even at 2.5 g/kg/day in exclusively parenterally nourished ELBW infants, to safely prevent EFA deficiency.</offsets></p></sec></body><back><ack id="S10"><p>We thank Eva Wissmann for excellent support with drug accountability.</p><p></p></ack><fn-group><fn fn-type="COI-statement" id="FN1"><p id="P31">A.R. received funding from Fresenius Kabi (Graz, Austria) to employ a clinical research nurse The other authors declare no conflicts of interest.</p></fn></fn-group><glossary><def-list><def-item><term>BPD</term><def><p>Bronchopulmonary dysplasia</p></def></def-item><def-item><term>DHA</term><def><p>Docosahexaenoic acid</p></def></def-item><def-item><term>EFA</term><def><p>Essential fatty acid</p></def></def-item><def-item><term>ELBW</term><def><p>Extremely low birth weight</p></def></def-item><def-item><term>ITT</term><def><p>Intention to treat</p></def></def-item><def-item><term>LC-PUFA</term><def><p>Long chain polyunsaturated fatty acid</p></def></def-item><def-item><term>MCT</term><def><p>Medium chain triglyceride</p></def></def-item><def-item><term>NEC</term><def><p>Necrotizing enterocolitis</p></def></def-item><def-item><term>PMA</term><def><p>Postmenstrual age</p></def></def-item><def-item><term>PN</term><def><p>Parenteral nutrition</p></def></def-item><def-item><term>PNAC</term><def><p>Parenteral nutrition associated cholestasis</p></def></def-item><def-item><term>RCT</term><def><p>Randomized controlled trial</p></def></def-item><def-item><term>ROP</term><def><p>Retinopathy of prematurity</p></def></def-item><def-item><term>SMOF-LE</term><def><p>Lipid emulsion composed of soybean oil, medium chain triglycerides, olive oil, and fish oil</p></def></def-item></def-list></glossary><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vohr</surname><given-names>BR</given-names></name><name><surname>Wright</surname><given-names>LL</given-names></name><name><surname>Dusick</surname><given-names>AM</given-names></name><name><surname>Perritt</surname><given-names>R</given-names></name><name><surname>Poole</surname><given-names>WK</given-names></name><name><surname>Tyson</surname><given-names>JE</given-names></name><etal></etal></person-group><article-title>Center differences and outcomes of extremely low birth weight infants</article-title><source>Pediatrics</source><year>2004</year><volume>113</volume><fpage>781</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15060228</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>DA</given-names></name></person-group><article-title>Liver complications of pediatric parenteral nutrition—epidemiology</article-title><source>Nutrition</source><year>1998</year><volume>14</volume><fpage>153</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9437702</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zambrano</surname><given-names>E</given-names></name><name><surname>El-Hennawy</surname><given-names>M</given-names></name><name><surname>Ehrenkranz</surname><given-names>RA</given-names></name><name><surname>Zelterman</surname><given-names>D</given-names></name><name><surname>Reyes-Mugica</surname><given-names>M</given-names></name></person-group><article-title>Total parenteral nutrition induced liver pathology: an autopsy series of 24 newborn cases</article-title><source>Pediatr Dev Pathol</source><year>2004</year><volume>7</volume><fpage>425</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">15547767</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanek</surname><given-names>VW</given-names></name><name><surname>Seidner</surname><given-names>DL</given-names></name><name><surname>Allen</surname><given-names>P</given-names></name><name><surname>Bistrian</surname><given-names>B</given-names></name><name><surname>Collier</surname><given-names>S</given-names></name><name><surname>Gura</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>A.S.P.E.N. position paper: clinical role for alternative intravenous fat emulsions</article-title><source>Nutr Clin Pract</source><year>2012</year><volume>27</volume><fpage>150</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">22378798</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>BA</given-names></name><name><surname>Taylor</surname><given-names>OA</given-names></name><name><surname>Prendergast</surname><given-names>DR</given-names></name><name><surname>Zimmerman</surname><given-names>TL</given-names></name><name><surname>Von Furstenberg</surname><given-names>R</given-names></name><name><surname>Moore</surname><given-names>DD</given-names></name><etal></etal></person-group><article-title>Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR</article-title><source>Pediatr Res</source><year>2007</year><volume>62</volume><fpage>301</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17622954</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Aerde</surname><given-names>JE</given-names></name><name><surname>Duerksen</surname><given-names>DR</given-names></name><name><surname>Gramlich</surname><given-names>L</given-names></name><name><surname>Meddings</surname><given-names>JB</given-names></name><name><surname>Chan</surname><given-names>G</given-names></name><name><surname>Thomson</surname><given-names>AB</given-names></name><etal></etal></person-group><article-title>Intravenous fish oil emulsion attenuates total parenteral nutrition-induced cholestasis in newborn piglets</article-title><source>Pediatr Res</source><year>1999</year><volume>45</volume><fpage>202</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10022591</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Meijer</surname><given-names>VE</given-names></name><name><surname>Gura</surname><given-names>KM</given-names></name><name><surname>Le</surname><given-names>HD</given-names></name><name><surname>Meisel</surname><given-names>JA</given-names></name><name><surname>Puder</surname><given-names>M</given-names></name></person-group><article-title>Fish oil-based lipid emulsions prevent and reverse parenteral nutrition-associated liver disease: the Boston experience</article-title><source>JPEN J Parenter Enteral Nutr</source><year>2009</year><volume>33</volume><fpage>541</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">19571170</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>IR</given-names></name><name><surname>Sterescu</surname><given-names>A</given-names></name><name><surname>Pencharz</surname><given-names>PB</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Wales</surname><given-names>PW</given-names></name></person-group><article-title>Changing the paradigm: omegaven for the treatment of liver failure in pediatric short bowel syndrome</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2009</year><volume>48</volume><fpage>209</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">19179884</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biesboer</surname><given-names>AN</given-names></name><name><surname>Stoehr</surname><given-names>NA</given-names></name></person-group><article-title>A product review of alternative oil-based intravenous fat emulsions</article-title><source>Nutr Clin Pract</source><year>2016</year><volume>31</volume><fpage>610</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">27528126</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanek</surname><given-names>VW</given-names></name><name><surname>Seidner</surname><given-names>DL</given-names></name><name><surname>Allen</surname><given-names>P</given-names></name><name><surname>Bistrian</surname><given-names>B</given-names></name><name><surname>Collier</surname><given-names>S</given-names></name><name><surname>Gura</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Update to A.S.P.E.N. position paper: clinical role for alternative intravenous fat emulsions</article-title><source>Nutr Clin Pract</source><year>2014</year><volume>29</volume><fpage>841</fpage><pub-id pub-id-type="pmid">25392455</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><collab>American Academy of Pediatrics</collab><article-title>Levels of neonatal care</article-title><source>Pediatrics</source><year>2012</year><volume>130</volume><fpage>587</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">22926177</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fergusson</surname><given-names>D</given-names></name><name><surname>Aaron</surname><given-names>SD</given-names></name><name><surname>Guyatt</surname><given-names>G</given-names></name><name><surname>Hebert</surname><given-names>P</given-names></name></person-group><article-title>Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis</article-title><source>BMJ</source><year>2002</year><volume>325</volume><fpage>652</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">12242181</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Errath</surname><given-names>M</given-names></name><name><surname>Berghold</surname><given-names>A</given-names></name><name><surname>Ofner</surname><given-names>P</given-names></name><name><surname>Quehenberger</surname><given-names>F</given-names></name></person-group><article-title>Randomizer for clinical trials 1.8.1</article-title><date-in-citation>Accessed July 31, 2017</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="https://www.meduniwien.ac.at/randomizer/web/about.php">https://www.meduniwien.ac.at/randomizer/web/about.php</ext-link>.</comment></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaffer</surname><given-names>ML</given-names></name><name><surname>Kunselman</surname><given-names>AR</given-names></name><name><surname>Watterberg</surname><given-names>KL</given-names></name></person-group><article-title>Analysis of neonatal clinical trials with twin births</article-title><source>BMC Med Res Methodol</source><year>2009</year><volume>9</volume><fpage>12</fpage><pub-id pub-id-type="pmid">19245713</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koletzko</surname><given-names>B</given-names></name><name><surname>Goulet</surname><given-names>O</given-names></name><name><surname>Hunt</surname><given-names>J</given-names></name><name><surname>Krohn</surname><given-names>K</given-names></name><name><surname>Shamir</surname><given-names>R</given-names></name><collab>Parenteral Nutrition Guidelines Working G</collab><etal></etal></person-group><article-title>1. Guidelines on Paediatric Parenteral Nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), Supported by the European Society of Paediatric Research (ESPR)</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2005</year><volume>41</volume><issue>Suppl 2</issue><fpage>S1</fpage><lpage>87</lpage></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Repa</surname><given-names>A</given-names></name><name><surname>Lochmann</surname><given-names>R</given-names></name><name><surname>Unterasinger</surname><given-names>L</given-names></name><name><surname>Weber</surname><given-names>M</given-names></name><name><surname>Berger</surname><given-names>A</given-names></name><name><surname>Haiden</surname><given-names>N</given-names></name></person-group><article-title>Aggressive nutrition in extremely low birth weight infants: impact on parenteral nutrition associated cholestasis and growth</article-title><source>PeerJ</source><year>2016</year><volume>4</volume><fpage>e2483</fpage><pub-id pub-id-type="pmid">27688976</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klebermass-Schrehof</surname><given-names>K</given-names></name><name><surname>Wald</surname><given-names>M</given-names></name><name><surname>Schwindt</surname><given-names>J</given-names></name><name><surname>Grill</surname><given-names>A</given-names></name><name><surname>Prusa</surname><given-names>AR</given-names></name><name><surname>Haiden</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Less invasive surfactant administration in extremely preterm infants: impact on mortality and morbidity</article-title><source>Neonatology</source><year>2013</year><volume>103</volume><fpage>252</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">23446061</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenton</surname><given-names>TR</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name></person-group><article-title>A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants</article-title><source>BMC Pediatr</source><year>2013</year><volume>13</volume><fpage>59</fpage><pub-id pub-id-type="pmid">23601190</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>T</given-names></name><name><surname>Fenton</surname><given-names>TR</given-names></name></person-group><article-title>Research bulk calculator 2013</article-title><date-in-citation>Accessed July 31, 2017</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="http://ucalgary.ca/fenton/2013chart">http://ucalgary.ca/fenton/2013chart</ext-link>.</comment></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>MC</given-names></name><name><surname>Kliegman</surname><given-names>RM</given-names></name></person-group><article-title>Necrotizing enterocolitis: treatment based on staging criteria</article-title><source>Pediatr Clin North Am</source><year>1986</year><volume>33</volume><fpage>179</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">3081865</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Repa</surname><given-names>A</given-names></name><name><surname>Thanhaeuser</surname><given-names>M</given-names></name><name><surname>Endress</surname><given-names>D</given-names></name><name><surname>Weber</surname><given-names>M</given-names></name><name><surname>Kreissl</surname><given-names>A</given-names></name><name><surname>Binder</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Probiotics (Lactobacillus acidophilus and Bifidobacterium infantis) prevent NEC in VLBW infants fed breast milk but not formula [corrected]</article-title><source>Pediatr Res</source><year>2015</year><volume>77</volume><fpage>381</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">25423074</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pammi</surname><given-names>M</given-names></name><name><surname>Abrams</surname><given-names>SA</given-names></name></person-group><article-title>Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants</article-title><source>Cochrane Database Syst Rev</source><year>2015</year><issue>5</issue><comment>CD007137</comment></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>PS</given-names></name></person-group><article-title>Diagnosis, evaluation, and management of patent ductus arteriosus in preterm neonates</article-title><source>JAMA Pediatr</source><year>2015</year><volume>169</volume><fpage>863</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">26168357</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steiner</surname><given-names>M</given-names></name><name><surname>Salzer</surname><given-names>U</given-names></name><name><surname>Baumgartner</surname><given-names>S</given-names></name><name><surname>Waldhoer</surname><given-names>T</given-names></name><name><surname>Klebermass-Schrehof</surname><given-names>K</given-names></name><name><surname>Wald</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Intravenous sildenafil i.v. as rescue treatment for refractory pulmonary hypertension in extremely preterm infants</article-title><source>Klin Padiatr</source><year>2014</year><volume>226</volume><fpage>211</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">25010126</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>A</given-names></name><name><surname>Stauffer</surname><given-names>ME</given-names></name><name><surname>Kaufman</surname><given-names>AS</given-names></name></person-group><article-title>Defining medication adherence in individual patients</article-title><source>Patient Prefer Adherence</source><year>2015</year><volume>9</volume><fpage>893</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">26170639</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albers</surname><given-names>MJ</given-names></name><name><surname>de Gast-Bakker</surname><given-names>DA</given-names></name><name><surname>van Dam</surname><given-names>NA</given-names></name><name><surname>Madern</surname><given-names>GC</given-names></name><name><surname>Tibboel</surname><given-names>D</given-names></name></person-group><article-title>Male sex predisposes the newborn surgical patient to parenteral nutrition-associated cholestasis and to sepsis</article-title><source>Arch Surg</source><year>2002</year><volume>137</volume><fpage>789</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">12093333</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beath</surname><given-names>SV</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name><name><surname>Papadopoulou</surname><given-names>A</given-names></name><name><surname>Khan</surname><given-names>AR</given-names></name><name><surname>Buick</surname><given-names>RG</given-names></name><name><surname>Corkery</surname><given-names>JJ</given-names></name><etal></etal></person-group><article-title>Parenteral nutrition-related cholestasis in postsurgical neonates: multivariate analysis of risk factors</article-title><source>J Pediatr Surg</source><year>1996</year><volume>31</volume><fpage>604</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8801324</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rangel</surname><given-names>SJ</given-names></name><name><surname>Calkins</surname><given-names>CM</given-names></name><name><surname>Cowles</surname><given-names>RA</given-names></name><name><surname>Barnhart</surname><given-names>DC</given-names></name><name><surname>Huang</surname><given-names>EY</given-names></name><name><surname>Abdullah</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Parenteral nutrition-associated cholestasis: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review</article-title><source>J Pediatr Surg</source><year>2012</year><volume>47</volume><fpage>225</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">22244423</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beale</surname><given-names>EF</given-names></name><name><surname>Nelson</surname><given-names>RM</given-names></name><name><surname>Bucciarelli</surname><given-names>RL</given-names></name><name><surname>Donnelly</surname><given-names>WH</given-names></name><name><surname>Eitzman</surname><given-names>DV</given-names></name></person-group><article-title>Intrahepatic cholestasis associated with parenteral nutrition in premature infants</article-title><source>Pediatrics</source><year>1979</year><volume>64</volume><fpage>342</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">113770</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>DK</given-names></name><name><surname>Skinner</surname><given-names>D</given-names></name><name><surname>Guarda</surname><given-names>S</given-names></name><name><surname>Choudhury</surname><given-names>S</given-names></name><name><surname>Sideris</surname><given-names>J</given-names></name><name><surname>Barnum</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Obtaining consent from both parents for pediatric research: what does “reasonably available” mean?</article-title><source>Pediatrics</source><year>2013</year><volume>131</volume><fpage>e223</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23266920</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hojsak</surname><given-names>I</given-names></name><name><surname>Colomb</surname><given-names>V</given-names></name><name><surname>Braegger</surname><given-names>C</given-names></name><name><surname>Bronsky</surname><given-names>J</given-names></name><name><surname>Campoy</surname><given-names>C</given-names></name><name><surname>Domellof</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>ESPGHAN Committee on nutrition position paper. intravenous lipid emulsions and risk of hepatotoxicity in infants and children: a systematic review and meta-analysis</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2016</year><volume>62</volume><fpage>776</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">26825766</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>K</given-names></name><name><surname>Stoll</surname><given-names>B</given-names></name><name><surname>Chacko</surname><given-names>S</given-names></name><name><surname>Saenz de Pipaon</surname><given-names>M</given-names></name><name><surname>Lauridsen</surname><given-names>C</given-names></name><name><surname>Gray</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Vitamin E in new-generation lipid emulsions protects against parenteral nutrition-associated liver disease in parenteral nutrition-fed preterm pigs</article-title><source>JPEN J Parenter Enteral Nutr</source><year>2016</year><volume>40</volume><fpage>656</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">25596209</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beken</surname><given-names>S</given-names></name><name><surname>Dilli</surname><given-names>D</given-names></name><name><surname>Fettah</surname><given-names>ND</given-names></name><name><surname>Kabatas</surname><given-names>EU</given-names></name><name><surname>Zenciroglu</surname><given-names>A</given-names></name><name><surname>Okumus</surname><given-names>N</given-names></name></person-group><article-title>The influence of fish-oil lipid emulsions on retinopathy of prematurity in very low birth weight infants: a randomized controlled trial</article-title><source>Early Hum Dev</source><year>2014</year><volume>90</volume><fpage>27</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">24314586</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Ascenzo</surname><given-names>R</given-names></name><name><surname>Savini</surname><given-names>S</given-names></name><name><surname>Biagetti</surname><given-names>C</given-names></name><name><surname>Bellagamba</surname><given-names>MP</given-names></name><name><surname>Marchionni</surname><given-names>P</given-names></name><name><surname>Pompilio</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Higher docosahexaenoic acid, lower arachidonic acid and reduced lipid tolerance with high doses of a lipid emulsion containing 15% fish oil: a randomized clinical trial</article-title><source>Clin Nutr</source><year>2014</year><volume>33</volume><fpage>1002</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">24525115</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savini</surname><given-names>S</given-names></name><name><surname>D’Ascenzo</surname><given-names>R</given-names></name><name><surname>Biagetti</surname><given-names>C</given-names></name><name><surname>Serpentini</surname><given-names>G</given-names></name><name><surname>Pompilio</surname><given-names>A</given-names></name><name><surname>Bartoli</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>The effect of 5 intravenous lipid emulsions on plasma phytosterols in preterm infants receiving parenteral nutrition: a randomized clinical trial</article-title><source>Am J Clin Nutr</source><year>2013</year><volume>98</volume><fpage>312</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">23761482</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vlaardingerbroek</surname><given-names>H</given-names></name><name><surname>Vermeulen</surname><given-names>MJ</given-names></name><name><surname>Carnielli</surname><given-names>VP</given-names></name><name><surname>Vaz</surname><given-names>FM</given-names></name><name><surname>van den Akker</surname><given-names>CH</given-names></name><name><surname>van Goudoever</surname><given-names>JB</given-names></name></person-group><article-title>Growth and fatty acid profiles of VLBW infants receiving a multicomponent lipid emulsion from birth</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2014</year><volume>58</volume><fpage>417</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">24667866</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>IR</given-names></name><name><surname>Grant</surname><given-names>RC</given-names></name><name><surname>Pencharz</surname><given-names>PB</given-names></name><name><surname>de Silva</surname><given-names>N</given-names></name><name><surname>Feldman</surname><given-names>BM</given-names></name><name><surname>Fitzgerald</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Preventing the progression of intestinal failure-associated liver disease in infants using a composite lipid emulsion</article-title><source>JPEN J Parenter Enteral Nutr</source><year>2016</year><volume>41</volume><fpage>866</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">26838529</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jobe</surname><given-names>AH</given-names></name></person-group><article-title>Mechanisms of lung injury and bronchopulmonary dysplasia</article-title><source>Am J Perinatol</source><year>2016</year><volume>33</volume><fpage>1076</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">27603539</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>V</given-names></name><name><surname>Glover</surname><given-names>R</given-names></name><name><surname>Malviya</surname><given-names>MN</given-names></name></person-group><article-title>Alternative lipid emulsions versus pure soy oil based lipid emulsions for parenterally fed preterm infants</article-title><source>Cochrane Database Syst Rev</source><year>2015</year><issue>12</issue><fpage>CD009172</fpage><pub-id pub-id-type="pmid">26630252</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>CT</given-names></name><name><surname>Makrides</surname><given-names>M</given-names></name><name><surname>McPhee</surname><given-names>AJ</given-names></name><name><surname>Sullivan</surname><given-names>TR</given-names></name><name><surname>Davis</surname><given-names>PG</given-names></name><name><surname>Thio</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Docosahexaenoic acid and bronchopulmonary dysplasia in preterm infants</article-title><source>N Engl J Med</source><year>2017</year><volume>376</volume><fpage>1245</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">28355511</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woldesenbet</surname><given-names>M</given-names></name><name><surname>Rosenfeld</surname><given-names>CR</given-names></name><name><surname>Ramilo</surname><given-names>O</given-names></name><name><surname>Johnson-Welch</surname><given-names>S</given-names></name><name><surname>Perlman</surname><given-names>JM</given-names></name></person-group><article-title>Severe neonatal hypoxic respiratory failure correlates with histological chorioamnionitis and raised concentrations of interleukin 6 (IL6), IL8 and C-reactive protein</article-title><source>Arch Dis Child Fetal Neonatal Ed</source><year>2008</year><volume>93</volume><fpage>F413</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">18192328</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>A</given-names></name><name><surname>Sosenko</surname><given-names>IR</given-names></name><name><surname>Chandar</surname><given-names>J</given-names></name><name><surname>Hummler</surname><given-names>H</given-names></name><name><surname>Claure</surname><given-names>N</given-names></name><name><surname>Bancalari</surname><given-names></given-names></name></person-group><article-title>Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less</article-title><source>J Pediatr</source><year>1996</year><volume>128</volume><fpage>470</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8618179</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>LE</given-names></name></person-group><article-title>Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture</article-title><source>Invest Ophthalmol Vis Sci</source><year>2008</year><volume>49</volume><fpage>5177</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">18708611</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brion</surname><given-names>LP</given-names></name><name><surname>Bell</surname><given-names>EF</given-names></name><name><surname>Raghuveer</surname><given-names>TS</given-names></name></person-group><article-title>Vitamin E supplementation for prevention of morbidity and mortality in preterm infants</article-title><source>Cochrane Database Syst Rev</source><year>2003</year><issue>4</issue><fpage>CD003665</fpage></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawlik</surname><given-names>D</given-names></name><name><surname>Lauterbach</surname><given-names>R</given-names></name><name><surname>Walczak</surname><given-names>M</given-names></name><name><surname>Hurkala</surname><given-names>J</given-names></name><name><surname>Sherman</surname><given-names>MP</given-names></name></person-group><article-title>Fish-oil fat emulsion supplementation reduces the risk of retinopathy in very low birth weight infants: a prospective, randomized study</article-title><source>JPEN J Parenter Enteral Nutr</source><year>2014</year><volume>38</volume><fpage>711</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">23963690</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vayalthrikkovil</surname><given-names>S</given-names></name><name><surname>Bashir</surname><given-names>RA</given-names></name><name><surname>Rabi</surname><given-names>Y</given-names></name><name><surname>Amin</surname><given-names>H</given-names></name><name><surname>Spence</surname><given-names>JM</given-names></name><name><surname>Robertson</surname><given-names>HL</given-names></name><etal></etal></person-group><article-title>Parenteral fish-oil lipid emulsions in the prevention of severe retinopathy of prematurity: a systematic review and meta-analysis</article-title><source>Am J Perinatol</source><year>2016</year><volume>34</volume><fpage>705</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">27992937</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlotzer</surname><given-names>E</given-names></name><name><surname>Kanning</surname><given-names>U</given-names></name></person-group><article-title>Elimination and tolerance of a new parenteral lipid emulsion (SMOF)—a double-blind cross-over study in healthy male volunteers</article-title><source>Ann Nutr Metab</source><year>2004</year><volume>48</volume><fpage>263</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15331886</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooke</surname><given-names>RJ</given-names></name><name><surname>Ainsworth</surname><given-names>SB</given-names></name><name><surname>Fenton</surname><given-names>AC</given-names></name></person-group><article-title>Postnatal growth retardation: a universal problem in preterm infants</article-title><source>Arch Dis Child Fetal Neonatal Ed</source><year>2004</year><volume>89</volume><fpage>F428</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">15321963</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calder</surname><given-names>PC</given-names></name></person-group><article-title>Docosahexaenoic Acid</article-title><source>Ann Nutr Metab</source><year>2016</year><volume>69</volume><issue>Suppl 1</issue><fpage>7</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">27842299</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Pei</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Xiang</surname><given-names>B</given-names></name></person-group><article-title>Safety and efficacy of parenteral fish oil-containing lipid emulsions in premature neonates</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2015</year><volume>60</volume><fpage>708</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">25514619</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlson</surname><given-names>SE</given-names></name><name><surname>Werkman</surname><given-names>SH</given-names></name><name><surname>Peeples</surname><given-names>JM</given-names></name><name><surname>Cooke</surname><given-names>RJ</given-names></name><name><surname>Tolley</surname><given-names>EA</given-names></name></person-group><article-title>Arachidonic acid status correlates with first year growth in preterm infants</article-title><source>Proc Natl Acad Sci USA</source><year>1993</year><volume>90</volume><fpage>1073</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8430076</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Figure</label><caption><p>Flow chart showing enrollment with reasons for study exclusion and analysis.</p></caption><graphic xlink:href="emss-75734-f001"></graphic></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table I</label><caption><title>Demographic characteristics</title></caption><table frame="box" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">SMOF-LE (n = 110)</th><th align="center" rowspan="1" colspan="1">S-LE (n = 113)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Obstetric parameters</td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Multiple pregnancy</td><td align="center" rowspan="1" colspan="1">30 (27)</td><td align="center" rowspan="1" colspan="1">36 (32)</td></tr><tr><td align="left" rowspan="1" colspan="1">Cesarean delivery</td><td align="center" rowspan="1" colspan="1">100 (91)</td><td align="center" rowspan="1" colspan="1">101 (89)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prenatal steroids (full course)</td><td align="center" rowspan="1" colspan="1">69 (63)</td><td align="center" rowspan="1" colspan="1">65 (59)</td></tr><tr><td align="left" rowspan="1" colspan="1">PROM</td><td align="center" rowspan="1" colspan="1">38 (35)</td><td align="center" rowspan="1" colspan="1">42 (37)</td></tr><tr><td align="left" rowspan="1" colspan="1">Preeclampsia</td><td align="center" rowspan="1" colspan="1">16 (15)</td><td align="center" rowspan="1" colspan="1">16 (14)</td></tr><tr><td align="left" rowspan="1" colspan="1">Neonatal parameters</td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Umbilical artery pH</td><td align="center" rowspan="1" colspan="1">7.31 [7.25 to 7.36] <xref ref-type="table-fn" rid="TFN3">*</xref></td><td align="center" rowspan="1" colspan="1">7.30 [7.24 to 7.35] <xref ref-type="table-fn" rid="TFN4">†</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Apgar—5 min</td><td align="center" rowspan="1" colspan="1">8 [8 to 9]</td><td align="center" rowspan="1" colspan="1">8 [8 to 9] <xref ref-type="table-fn" rid="TFN5">‡</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Male sex</td><td align="center" rowspan="1" colspan="1">64 (58)</td><td align="center" rowspan="1" colspan="1">73 (65)</td></tr><tr><td align="left" rowspan="1" colspan="1">Surfactant</td><td align="center" rowspan="1" colspan="1">97 (88)</td><td align="center" rowspan="1" colspan="1">98 (87)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gestational age (wk+d)</td><td align="center" rowspan="1" colspan="1">25 + 6 [24 + 6 to 27 + 3]</td><td align="center" rowspan="1" colspan="1">26 + 2 [25 + 0 to 28 + 0]</td></tr><tr><td align="left" rowspan="1" colspan="1">Birth weight (g)</td><td align="center" rowspan="1" colspan="1">788 [648 to 891]</td><td align="center" rowspan="1" colspan="1">760 [610 to 884]</td></tr><tr><td align="left" rowspan="1" colspan="1">     Z score</td><td align="center" rowspan="1" colspan="1">−0.4 [−1.1 to −0.2]</td><td align="center" rowspan="1" colspan="1">−0.7 [−1.4 to − 0.2]</td></tr><tr><td align="left" rowspan="1" colspan="1">Birth length (cm)</td><td align="center" rowspan="1" colspan="1">34 [31 to 35] <xref ref-type="table-fn" rid="TFN5">‡</xref></td><td align="center" rowspan="1" colspan="1">33 [31 to 35] <xref ref-type="table-fn" rid="TFN5">‡</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">     Z score</td><td align="center" rowspan="1" colspan="1">−0.3 [−1.1 to 0.7] <xref ref-type="table-fn" rid="TFN5">‡</xref></td><td align="center" rowspan="1" colspan="1">−0.3 [−1.5 to 0.4] <xref ref-type="table-fn" rid="TFN5">‡</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Birth head circumference (cm)</td><td align="center" rowspan="1" colspan="1">24 [23 to 25] <xref ref-type="table-fn" rid="TFN6">§</xref></td><td align="center" rowspan="1" colspan="1">24 [23 to 25]</td></tr><tr><td align="left" rowspan="1" colspan="1">     Z score</td><td align="center" rowspan="1" colspan="1">−0.1 [−0.7 to 0.6] <xref ref-type="table-fn" rid="TFN6">§</xref></td><td align="center" rowspan="1" colspan="1">−0.2 [−1.0 to −0.2]</td></tr><tr><td align="left" rowspan="1" colspan="1">Small for gestational age</td><td align="center" rowspan="1" colspan="1">22 (20)</td><td align="center" rowspan="1" colspan="1">38 (34)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p id="P32"><italic>PROM</italic>, premature rupture of membranes; <italic>S-LE</italic> soybean oil-based lipid emulsion.</p></fn><fn id="TFN2"><p id="P33">Analysis by ITT. Categorical data are presented as numbers with percentages in round parentheses and were tested using the <italic>χ</italic><sup>2</sup> test. Continuous data are presented as the median and IQR in squared parentheses and were tested using the Mann-Whitney <italic>U</italic> Test.</p></fn><fn id="TFN3"><label>*</label><p id="P34">Data of 15 patients missing.</p></fn><fn id="TFN4"><label>†</label><p id="P35">Data of 21 patients missing.</p></fn><fn id="TFN5"><label>‡</label><p id="P36">Data of 2 patients missing.</p></fn><fn id="TFN6"><label>§</label><p id="P37">Data of 1 patient missing.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float" orientation="portrait"><label>Table II</label><caption><title>Neonatal outcome</title></caption><table frame="box" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Outcome</th><th align="center" rowspan="1" colspan="1">SMOF-LE (n = 110)</th><th align="center" rowspan="1" colspan="1">S-LE (n = 113)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Primary outcome and liver function (peak levels throughout the study)</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">PNAC</td><td align="center" rowspan="1" colspan="1">11 (10)</td><td align="center" rowspan="1" colspan="1">18 (16)</td><td align="center" rowspan="1" colspan="1">.20</td></tr><tr><td align="left" rowspan="1" colspan="1">    Occurrence (day of life)</td><td align="center" rowspan="1" colspan="1">23 [11-36]</td><td align="center" rowspan="1" colspan="1">20 [9-42]</td><td align="center" rowspan="1" colspan="1">.95</td></tr><tr><td align="left" rowspan="1" colspan="1">    Death<xref ref-type="table-fn" rid="TFN10">*</xref></td><td align="center" rowspan="1" colspan="1">2 (18)</td><td align="center" rowspan="1" colspan="1">3 (16)</td><td align="center" rowspan="1" colspan="1">.91</td></tr><tr><td align="left" rowspan="1" colspan="1">    Rescue therapy using fish oil<xref ref-type="table-fn" rid="TFN10">*</xref></td><td align="center" rowspan="1" colspan="1">3 (27)</td><td align="center" rowspan="1" colspan="1">4 (22)</td><td align="center" rowspan="1" colspan="1">.76</td></tr><tr><td align="left" rowspan="1" colspan="1">    Normalized before discharge<xref ref-type="table-fn" rid="TFN10">*</xref></td><td align="center" rowspan="1" colspan="1">6 (55)</td><td align="center" rowspan="1" colspan="1">5 (28)</td><td align="center" rowspan="1" colspan="1">.15</td></tr><tr><td align="left" rowspan="1" colspan="1">Conjugated bilirubin (mg/dL)</td><td align="center" rowspan="1" colspan="1">0 [0-0.22]</td><td align="center" rowspan="1" colspan="1">0 [0-0.38]</td><td align="center" rowspan="1" colspan="1">.67</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>γ</italic>-GT (U/mL)</td><td align="center" rowspan="1" colspan="1">148 [95-243] <xref ref-type="table-fn" rid="TFN11">†</xref></td><td align="center" rowspan="1" colspan="1">157 [101-217] <xref ref-type="table-fn" rid="TFN12">‡</xref></td><td align="center" rowspan="1" colspan="1">.94</td></tr><tr><td align="left" rowspan="1" colspan="1">AST (U/mL)</td><td align="center" rowspan="1" colspan="1">41 [32-67] <xref ref-type="table-fn" rid="TFN11">†</xref></td><td align="center" rowspan="1" colspan="1">48 [34-80] <xref ref-type="table-fn" rid="TFN12">‡</xref></td><td align="center" rowspan="1" colspan="1">.13</td></tr><tr><td align="left" rowspan="1" colspan="1">ALT (U/mL)</td><td align="center" rowspan="1" colspan="1">32 [30-41] <xref ref-type="table-fn" rid="TFN11">†</xref></td><td align="center" rowspan="1" colspan="1">34 [29-45] <xref ref-type="table-fn" rid="TFN12">‡</xref></td><td align="center" rowspan="1" colspan="1">.40</td></tr><tr><td align="left" rowspan="1" colspan="1">AP (U/mL)</td><td align="center" rowspan="1" colspan="1">518 [396-665] <xref ref-type="table-fn" rid="TFN11">†</xref></td><td align="center" rowspan="1" colspan="1">494 [376-671] <xref ref-type="table-fn" rid="TFN12">‡</xref></td><td align="center" rowspan="1" colspan="1">.70</td></tr><tr><td align="left" rowspan="1" colspan="1">Neonatal morbidity</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Death</td><td align="center" rowspan="1" colspan="1">8 (7)</td><td align="center" rowspan="1" colspan="1">8 (7)</td><td align="center" rowspan="1" colspan="1">.96</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospitalization (d)</td><td align="center" rowspan="1" colspan="1">81 [59-105]</td><td align="center" rowspan="1" colspan="1">79 [63-97]</td><td align="center" rowspan="1" colspan="1">.69</td></tr><tr><td align="left" rowspan="1" colspan="1">Retinopathy of prematurity (any)</td><td align="center" rowspan="1" colspan="1">60 (58)</td><td align="center" rowspan="1" colspan="1">56 (55)</td><td align="center" rowspan="1" colspan="1">.69</td></tr><tr><td align="left" rowspan="1" colspan="1">    Highest grade (grade 1-5)</td><td align="center" rowspan="1" colspan="1">1 [0-2]</td><td align="center" rowspan="1" colspan="1">1 [0-2]</td><td align="center" rowspan="1" colspan="1">.63</td></tr><tr><td align="left" rowspan="1" colspan="1">    Requiring treatment (severe ROP)</td><td align="center" rowspan="1" colspan="1">9 (8)</td><td align="center" rowspan="1" colspan="1">10 (9)</td><td align="center" rowspan="1" colspan="1">.79</td></tr><tr><td align="left" rowspan="1" colspan="1">Sepsis, culture proven</td><td align="center" rowspan="1" colspan="1">24 (22)</td><td align="center" rowspan="1" colspan="1">26 (23)</td><td align="center" rowspan="1" colspan="1">.83</td></tr><tr><td align="left" rowspan="1" colspan="1">Intraventricular hemorrhage III/IV</td><td align="center" rowspan="1" colspan="1">12 (11)</td><td align="center" rowspan="1" colspan="1">9 (8)</td><td align="center" rowspan="1" colspan="1">.45</td></tr><tr><td align="left" rowspan="1" colspan="1">Cystic periventricular leukomalacia</td><td align="center" rowspan="1" colspan="1">3 (3)</td><td align="center" rowspan="1" colspan="1">4 (4)</td><td align="center" rowspan="1" colspan="1">.73</td></tr><tr><td align="left" rowspan="1" colspan="1">NEC ≥IIa</td><td align="center" rowspan="1" colspan="1">8 (7)</td><td align="center" rowspan="1" colspan="1">8 (7)</td><td align="center" rowspan="1" colspan="1">.96</td></tr><tr><td align="left" rowspan="1" colspan="1">Focal intestinal perforation</td><td align="center" rowspan="1" colspan="1">4 (4)</td><td align="center" rowspan="1" colspan="1">5 (4)</td><td align="center" rowspan="1" colspan="1">.77</td></tr><tr><td align="left" rowspan="1" colspan="1">Abdominal surgery</td><td align="center" rowspan="1" colspan="1">13 (12)</td><td align="center" rowspan="1" colspan="1">14 (12)</td><td align="center" rowspan="1" colspan="1">.90</td></tr><tr><td align="left" rowspan="1" colspan="1">Days on mechanical ventilation</td><td align="center" rowspan="1" colspan="1">6 [0-10]</td><td align="center" rowspan="1" colspan="1">6 [0-10]</td><td align="center" rowspan="1" colspan="1">.51</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic lung disease</td><td align="center" rowspan="1" colspan="1">19 (17)</td><td align="center" rowspan="1" colspan="1">21 (19)</td><td align="center" rowspan="1" colspan="1">.80</td></tr><tr><td align="left" rowspan="1" colspan="1">    Steroid treatment</td><td align="center" rowspan="1" colspan="1">11 (10)</td><td align="center" rowspan="1" colspan="1">17 (15)</td><td align="center" rowspan="1" colspan="1">.26</td></tr><tr><td align="left" rowspan="1" colspan="1">PDA requiring treatment</td><td align="center" rowspan="1" colspan="1">56 (51)</td><td align="center" rowspan="1" colspan="1">68 (60)</td><td align="center" rowspan="1" colspan="1">.16</td></tr><tr><td align="left" rowspan="1" colspan="1">    Number of ibuprofen cycles</td><td align="center" rowspan="1" colspan="1">2 [1-3]</td><td align="center" rowspan="1" colspan="1">2 [1-3]</td><td align="center" rowspan="1" colspan="1">.82</td></tr><tr><td align="left" rowspan="1" colspan="1">    Surgical ligation</td><td align="center" rowspan="1" colspan="1">5 (5)</td><td align="center" rowspan="1" colspan="1">6 (5)</td><td align="center" rowspan="1" colspan="1">.80</td></tr><tr><td align="left" rowspan="1" colspan="1">Pulmonary hypertension</td><td align="center" rowspan="1" colspan="1">23 (21)</td><td align="center" rowspan="1" colspan="1">31 (28)</td><td align="center" rowspan="1" colspan="1">.27</td></tr><tr><td align="left" rowspan="1" colspan="1">    iNO/sildenafil treatment</td><td align="center" rowspan="1" colspan="1">19 (17)</td><td align="center" rowspan="1" colspan="1">28 (25)</td><td align="center" rowspan="1" colspan="1">.18</td></tr></tbody></table><table-wrap-foot><fn id="TFN7"><p id="P38"><italic>ALT</italic>, Alanine transaminase; <italic>AST</italic>, Aspartate transaminase; <italic>AP</italic>, Alkaline phosphatase; <italic>GT</italic>, glutamyltransferase.</p></fn><fn id="TFN8"><p id="P39">Analysis by ITT. Categorical data are presented as numbers with percentages in round parentheses and were tested using the chi-square test. Continuous data are presented as median and interquartile range in squared parentheses and were tested using the Mann-Whitney <italic>U</italic> test. <italic>P</italic> values &lt;.05 were considered statistically significant.</p></fn><fn id="TFN9"><p id="P40">SI conversion factors: To convert bilirubin to µmol/L multiply values by 17.1, to convert triglycerides to mmol/L multiply values by .011.</p></fn><fn id="TFN10"><label>*</label><p id="P41">Percentage within the subgroup of infants with PNAC.</p></fn><fn id="TFN11"><label>†</label><p id="P42">Data of 2 patient missing.</p></fn><fn id="TFN12"><label>‡</label><p id="P43">Data of 1 patients missing.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float" orientation="portrait"><label>Table III</label><caption><title>Nutrition and growth</title></caption><table frame="box" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Outcome</th><th align="center" rowspan="1" colspan="1">SMOF-LE (n = 110)</th><th align="center" rowspan="1" colspan="1">S-LE (n = 113)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Study drug and nutrition</td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Therapy adherence &gt;80%</td><td align="center" rowspan="1" colspan="1">109 (99)</td><td align="center" rowspan="1" colspan="1">110 (97)</td><td align="center" rowspan="1" colspan="1">.33</td></tr><tr><td align="left" rowspan="1" colspan="1">Time on PN (d)</td><td align="center" rowspan="1" colspan="1">23 [17-37]</td><td align="center" rowspan="1" colspan="1">24 [17-35]</td><td align="center" rowspan="1" colspan="1">.87</td></tr><tr><td align="left" rowspan="1" colspan="1">Time on parenteral lipids (d)</td><td align="center" rowspan="1" colspan="1">20 [15-35]</td><td align="center" rowspan="1" colspan="1">21 [15-29]</td><td align="center" rowspan="1" colspan="1">.91</td></tr><tr><td align="left" rowspan="1" colspan="1">     Total parenteral lipids (g/kg)</td><td align="center" rowspan="1" colspan="1">38.2 [26.4-68.5]</td><td align="center" rowspan="1" colspan="1">39.0 [28.1-55.3]</td><td align="center" rowspan="1" colspan="1">.56</td></tr><tr><td align="left" rowspan="1" colspan="1">     Total study lipids (g/kg)</td><td align="center" rowspan="1" colspan="1">32.6 [21.3-63.8]</td><td align="center" rowspan="1" colspan="1">34.4 [23.0-50.8]</td><td align="center" rowspan="1" colspan="1">.57</td></tr><tr><td align="left" rowspan="1" colspan="1">Highest triglycerides (mg/dL)</td><td align="center" rowspan="1" colspan="1">208 [142-323] <xref ref-type="table-fn" rid="TFN14">*</xref></td><td align="center" rowspan="1" colspan="1">207 [147-305] <xref ref-type="table-fn" rid="TFN15">†</xref></td><td align="center" rowspan="1" colspan="1">.85</td></tr><tr><td align="left" rowspan="1" colspan="1">     Parenteral lipids at measurement</td><td align="center" rowspan="1" colspan="1">2.1 [1.5-2.5]<xref ref-type="table-fn" rid="TFN14">*</xref></td><td align="center" rowspan="1" colspan="1">2.0 [1.2-2.5]<xref ref-type="table-fn" rid="TFN15">†</xref></td><td align="center" rowspan="1" colspan="1">.30</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertriglyceridemia</td><td align="center" rowspan="1" colspan="1">39 (39)</td><td align="center" rowspan="1" colspan="1">38 (37)</td><td align="center" rowspan="1" colspan="1">.71</td></tr><tr><td align="left" rowspan="1" colspan="1">Feeding first wk (mL per feed/kg)</td><td align="center" rowspan="1" colspan="1">3.3 [2.3-4.1]</td><td align="center" rowspan="1" colspan="1">3.1 [2.3-4.1]</td><td align="center" rowspan="1" colspan="1">.55</td></tr><tr><td align="left" rowspan="1" colspan="1">Mothers milk at discharge (any)</td><td align="center" rowspan="1" colspan="1">85 (75)</td><td align="center" rowspan="1" colspan="1">80 (69)</td><td align="center" rowspan="1" colspan="1">.29</td></tr><tr><td align="left" rowspan="1" colspan="1">Anthropometry at discharge <xref ref-type="table-fn" rid="TFN16">‡</xref></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Weight at discharge (g)</td><td align="center" rowspan="1" colspan="1">2594 [2124 to 3029]</td><td align="center" rowspan="1" colspan="1">2479 [2175 to 2956]</td><td align="center" rowspan="1" colspan="1">.23</td></tr><tr><td align="left" rowspan="1" colspan="1">     Δ z score (birth to end of study)</td><td align="center" rowspan="1" colspan="1">−0.7 [−1.0 to −0.2]</td><td align="center" rowspan="1" colspan="1">−0.7 [−1.1 to −0.2]</td><td align="center" rowspan="1" colspan="1">.84</td></tr><tr><td align="left" rowspan="1" colspan="1">Length (cm)</td><td align="center" rowspan="1" colspan="1">45 [42.5 to 47]</td><td align="center" rowspan="1" colspan="1">44 [41.5 to 47]</td><td align="center" rowspan="1" colspan="1">.14</td></tr><tr><td align="left" rowspan="1" colspan="1">     Δ z Score (birth to end of study)</td><td align="center" rowspan="1" colspan="1">−1.4 [−2.3 to 0.8]</td><td align="center" rowspan="1" colspan="1">−1.5 [−2.1 to 1.0]</td><td align="center" rowspan="1" colspan="1">.64</td></tr><tr><td align="left" rowspan="1" colspan="1">Head circumference (cm)</td><td align="center" rowspan="1" colspan="1">32 [30.6 to 33.5]</td><td align="center" rowspan="1" colspan="1">32 [30.7 to 33.1]</td><td align="center" rowspan="1" colspan="1">.45</td></tr><tr><td align="left" rowspan="1" colspan="1">     Δ z Score (birth to end of study)</td><td align="center" rowspan="1" colspan="1">−1.0 [−1.7 to −0.3]</td><td align="center" rowspan="1" colspan="1">−1.0 [−1.6 to −0.3]</td><td align="center" rowspan="1" colspan="1">.92</td></tr></tbody></table><table-wrap-foot><fn id="TFN13"><p id="P44">Analysis by ITT. Categorical data are presented as numbers with percentages in round parentheses and were tested using the χ<sup>2</sup> test. Continuous data are presented as median and IQR in squared parentheses and were tested using the Mann-Whitney <italic>U</italic> Test. <italic>P</italic> values &lt;.05 were considered statistically significant.</p></fn><fn id="TFN14"><label>*</label><p id="P45">Data of 11 patients missing.</p></fn><fn id="TFN15"><label>†</label><p id="P46">Data of 10 patients missing.</p></fn><fn id="TFN16"><label>‡</label><p id="P47">For analysis of growth, infants who died were excluded (SMOF-LE, n = 104; S-LE, n = 101).</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" position="float" orientation="portrait"><label>Table IV</label><caption><title>Multivariable analysis on the risk for PNAC</title></caption><table frame="box" rules="groups"><thead><tr><th align="center" rowspan="1" colspan="1"></th><th align="center" colspan="3" rowspan="1">ITT (n = 223)<hr></hr></th><th align="center" colspan="3" rowspan="1">Per protocol (n = 206)<hr></hr></th></tr><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">aOR</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" rowspan="1" colspan="1">aOR</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">SMOF-LE</td><td align="center" rowspan="1" colspan="1">0.428</td><td align="center" rowspan="1" colspan="1">0.155-1.187</td><td align="center" rowspan="1" colspan="1">.10</td><td align="center" rowspan="1" colspan="1">0.457</td><td align="center" rowspan="1" colspan="1">0.155-1.347</td><td align="center" rowspan="1" colspan="1">.16</td></tr><tr><td align="left" rowspan="1" colspan="1">NEC/FIP/GI surgery</td><td align="center" rowspan="1" colspan="1">5.481</td><td align="center" rowspan="1" colspan="1">  1.894-15.868</td><td align="center" rowspan="1" colspan="1">  .002</td><td align="center" rowspan="1" colspan="1">5.016</td><td align="center" rowspan="1" colspan="1">  1.528-16.464</td><td align="center" rowspan="1" colspan="1">  .008</td></tr><tr><td align="left" rowspan="1" colspan="1">Time on PN (d)</td><td align="center" rowspan="1" colspan="1">1.051</td><td align="center" rowspan="1" colspan="1">1.023-1.080</td><td align="center" rowspan="1" colspan="1">&lt;.001</td><td align="center" rowspan="1" colspan="1">1.059</td><td align="center" rowspan="1" colspan="1">1.027-1.092</td><td align="center" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Feeding first wk (mL per feed/kg)</td><td align="center" rowspan="1" colspan="1">0.739</td><td align="center" rowspan="1" colspan="1">0.487-1.112</td><td align="center" rowspan="1" colspan="1">.16</td><td align="center" rowspan="1" colspan="1">0.665</td><td align="center" rowspan="1" colspan="1">0.413-1.073</td><td align="center" rowspan="1" colspan="1">.10</td></tr></tbody></table><table-wrap-foot><fn id="TFN17"><p id="P48">
<italic>FIP</italic>, focal intestinal perforation; <italic>GI</italic>, gastrointestinal.</p></fn><fn id="TFN18"><p id="P49">Analysis by ITT and per protocol. Binary logistic regression analysis showing the odds for the effect of SMOF-LE on PNAC compared with S-LE, adjusted for “compound outcome of NEC, FIP, and GI surgery,” time on parenteral nutrition and the median volume per enteral feed per kg birth weight in the first week of life. <italic>P</italic> values &lt; .05 were considered statistically significant.</p></fn></table-wrap-foot></table-wrap></floats-group></article>